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Abstract
Mechanism of Phospho-alpha-Tubulin-driven Motility in Human Breast
Epithelial Cells
by
Shatarupa De
Advisor: Professor Susan A. Rotenberg
Protein kinase C (PKC), an enzyme important in signaling pathways that give rise to various
cell phenotypes, has been closely associated with metastatic phenotypes of breast cancer.
Tissues from patients of varying degrees of tumorgenicity have shown an elevated expression
of the PKCα isoform as well as other diacylglycerol (DAG)-sensitive isoforms. Moreover,
independent studies with highly invasive breast cell lines, such as MDA-MB-231 cells, have
also shown an elevated level of PKCα. Therefore, PKCα has long been a therapeutic target
for breast cancer. Among its known substrates (recently identified by our laboratory), α6tubulin will, upon phosphorylation by PKC, enhance migration in breast epithelial cells. The
mechanistic pathway as to how a phosphorylated state of α-tubulin can confer motility in
breast epithelial cells was addressed in the present work.

Different approaches were

undertaken to dissect the role(s) played by phospho-α6-tubulin in enhancing cell migration: i)
extensive live cell imaging to quantitate microtubule dynamics, ii) immunofluorescence of
microtubules in fixed cells, iii) partitioning of phospho-α6-tubulin between particulate and
soluble phases, and iv) pull-down assays to determine effects on the small GTPases.

For

these studies, two mutants of α6-tubulin namely, S165D (pseudo-phosphorylated) and S165N
(phosphorylation-resistant), were used extensively. In addition, cells expressing wildtype
(WT)-α6-tubulin were treated with either the PKC-activating DAG-lactone or the pan-PKC
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inhibitor bis-indoleylmaleimide (BIM). Experiments were conducted in non-motile MCF10A cells that have a low expression level of PKC and therefore offer an ideal platform for
studying PKC-mediated changes. Some experiments were also conducted in MDA-MB-231
metastatic breast epithelial cells to re-affirm the role of phospho-α-tubulin in motility and
related phenotypes. Functionality of phospho-α-tubulin was also explored by examining its
interaction with the microtubule cargo protein MARCKS (a PKC-substrate), and membrane
proteins like IQGAP1 and Rac1 having known involvement in cell migration. Each α6tubulin mutant was studied for its effects on the distinct morphological glandular structures
that it produced in a 3D growth environment, in order to simulate an in vivo condition. This
study is the first of its kind to establish a detailed mechanism of cell movement driven by the
PKC substrate α-tubulin in human breast cells. The novel role of phospho-α-tubulin in
promoting motility will establish it as an important predictive marker for metastatic breast
cancer.
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Chapter 1: Introduction

1.1: Cell migration and the cytoskeleton
Cell migration is a multi-step process that involves an integration and coordination of
biochemical and biomechanical signals (Devreotes and Zigmond, 1988), and is essential for
sustaining various biological events in the cell. It involves the interplay of several proteins,
chiefly those of the cytoskeleton and plasma membrane. Interactions among signaling
molecules and cytoskeletal components generates forces near the cell periphery that enable
protrusion of cell leading edges, formation of new focal adhesion contacts at the front, with
simultaneous contraction and release of adhesion points from the rear ends (Lauffenburger
and Horwitz, 1996; Sheetz et al., 1999).
A key event in cell migration is the polymerization of actin filaments (F-acin) in the direction
of movement that provides the protrusive force for extending the cell leading edge (Li et al.,
2005). However, there is evidence that emphasizes the involvement of microtubules (MTs) in
cell migration (Liao et al., 1995; Ganguly et al., 2012). A central observation is that cells lose
their migratory phenotypes and fail to extend lamellipodia when MTs are depolymerized
(Ballestrem et al., 2000).
1.2: Microtubule structure and dynamics
Microtubules are cylindrical polymeric structures of α-β tubulin heterodimers (55 kDa) in the
cytoplasm of eukaryotic cells (Kirschner and Mitchison, 1986). Heterodimers are assembled
as a polarized array called a protofilament, thirteen of which are bundled together to make up
each MT (see Figure 1.1). During the growth phase of MTs, the heterodimers are assembled
into polymers such that a β-tubulin is exposed at the fast-growing (+) end and an α-tubulin is
1
	
  

	
  
	
  

Figure 1.1: Microtubule structure and dynamic instability (Akhmanova and Steinmetz, 2008).

exposed to the slow-growing (-) end. MTs are anchored by their (-) ends at the microtubule
organizing center (MTOC) while the free (+) ends lying near the cell periphery and there
display more rapid kinetics of polymerization and depolymerization. The rapid
polymerization-depolymerization intervals confer a dynamic behavior to MTs that is essential
for its role in cell migration, and cell division (Liao et al., 1995; Akhmanova and Steinmetz,
2008).
MTs primarily display two types of dynamic behaviors – ‘treadmilling’ and ‘dynamic
instability’.

The former involves addition of MT dimers at the (+) ends along with

disassociation at the (-) ends, thereby producing a flow of subunits from one end to the other
without affecting the net length. On the other hand, dynamic instability is confined to the ‘+’
2
	
  

	
  
	
  

end, and consists of alternating phases of growth (polymerization) and shrinkage
(depolymerization) interspersed with periods of catastrophes (transition from growth to
shortening) and rescues (transition from shortening to growth). In addition, MTs can pause
for a period of time during which they are neither growing nor shrinking (Van der Vaart et
al., 2009; Akhmanova and Steinmetz, 2008; Kirschner and Mitchison, 1986).
Metastasis is a complex process involving the participation of proteins associated with both
actin filaments and MT cytoskeleton, by which cancer cells migrate from one place to
another and invade neighboring or distant tissues. Because of its role in cell migration, MT
serves as an attractive target for chemotherapy against rapidly growing tumor cells like
lymphomas and leukemia, as well as in slow growing tumors like breast, ovary and lung
cancers (Honore et al., 2005;	
   Pasquier and Kavallaris, 2008; Jordan and Wilson, 2004;
Mooberry, 2011).

1.3: PKC structure and regulation
In 1977, Nishizuka’s group first identified protein kinase C (PKC) as the protein receptor for
phorbol ester tumor promoters, making it an important component in carcinogenesis
(Newton, 1997). Later, PKC was found to be involved in many biological processes
including development (Otte et al., 1991), memory (Alkon, 1989), and cell proliferation. The
PKC family of serine/threonine kinases is classified into three groups on the basis of their
mode of activation and structure of their regulatory domains (Nishizuka 1988). These are (1)
the conventional isoforms (cPKC; α, β, γ) which are activated by diacylglycerol (DAG) or
phorbol esters and Ca2+ (Figure 1.2); (2) the novel isoforms (nPKC; δ, , η, θ) which are
activated by DAG or phorbol esters but independent of Ca2+; and (3) the atypical isoforms
(aPKC; ζ and λ) that are unresponsive to Ca2+, DAG, and phorbol esters (Larsson 2006;
Koivunen et al., 2006). All of these PKC isoforms exhibit differential subcellular
3
	
  

	
  
	
  

Figure 1.2: Activation of conventional PKC by an extracellular signal via G-coupled receptors
(Koivunen et al., 2006).

localization, tissue expression, biochemical properties and functions, which suggests a
complexity in the cell signaling machinery that has yet to be elucidated (Urtreger et al.,
2012).
PKC plays a major role in signal transduction of a variety of extracellular stimuli. The
universally expressed conventional isoform, PKCα, is regulated downstream of G-coupled,
adhesion, growth, and a multitude of other receptors, that leads to the activation of
phospholipase C in the plasma membrane (Konopatskaya and Poole, 2009). This event
results in the cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) to yield two
secondary messengers, inositol 1,4,5-bisphosphate (IP3) and diacylglycerol (DAG). Once
produced, DAG and Ca2+ bind to PKCα resulting in activation and translocation of the
enzyme from cytoplasm to the membrane. After phosphorylation of PKCα protein substrates,
signal transduction proceeds through a cascade of reactions (Kennedy et al., 1992) that
culminate in phenotypes such as migration, proliferation, and cell morphology changes (Sun
and Rotenberg, 1999). In view of their complexity with regard to regulation, sub-cellular
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location, and differences in active site structure, individual PKC isoforms select specific
substrates as well as substrates shared with other isoforms.

1.4: PKC and breast cell motility
On account of its central role in transducing extracellular signals and cell proliferation, PKC
activity has been studied widely in normal and malignant breast tissues (Lonne et al., 2010).
Several studies have shown an active involvement of PKCα in breast cancer progression.
Although the majority of studies demonstrate the role of PKCα as a tumor promoter and
associate it with breast cancer progression, a few instances exist wherein PKCα was observed
to be down-regulated under the same pathological condition (Lonne et al., 2010; Urtreger et
al., 2012). Tumors of patients from varying degrees of malignancy, as well as highly
metastatic breast epithelial cells (like MDA-MB-231) have shown an overexpression of
PKCα. An increased level of PKCα has also been found to be associated with several markers
of tumor aggressiveness. Additionally, PKCα was implicated in epithelial to mesenchymal
transition of human breast cells (EMT) (Urtreger et al., 2012; Gordge et al., 1996). Recent
work from our laboratory has begun to shed light on this important area by identifying new
substrates of PKCα that pertain to breast cancer cell movement (Abeyweera and Rotenberg,
2007; Abeyweera et al., 2009; Chen et al., 2012).
The non-transformed, non-tumorigenic human mammary epithelial MCF-10A cell expresses
very low levels of PKCα. Hence, it offers a very low background for experiments seeking to
study the involvement of PKCα in specific pathways related to significant phenotypic
changes in human breast cells. Sun and Rotenberg (1999) reported the impact of engineered
over-expression of PKCα on growth properties and activities related to metastatic phenotype
in MCF-10A cells. Upon overexpressing PKCα, the cells exhibited the following features: (a)
decreased proliferative rate, (b) slowed passage through the cell cycle at G1 phase that
5
	
  

	
  
	
  

correlated with a 30-fold up-regulation of the cell cycle inhibitor p27kip, (c) altered steadystate levels of focal adhesion proteins (FAK, paxillin) and E-cadherin, (d) enlarged cell
morphology with prominent lamellipodia, and (e) dramatically increased cell motility.
Furthermore, the study provided the first indication that the small G-protein Rac1, but not
Cdc42 or RhoA, participates in PKCα-induced motility in MCF-10A transfected cells.
Since parental MCF-10A cells have very low PKCα activity and are weakly motile, it was
proposed that they express a putative inhibitor of the endogenous PKC that blocks epidermal
growth factor (EGF) mediated PKC activation. However, this inhibition was overcome by
addition of either a PKCα-selective membrane permeable DAG analogue (DAG-lactone) or
by over-expression of PKCα, both of which enhance cell motility. Once expressed in a cell,
PKCα is activated by EGF-induced intracellular DAG/Ca2+ resulting in motile behavior
(Abeyweera, Chen et al. 2009).

1.5: PKC and α6-tubulin
The precise mechanism by which PKCα drives cell motility remained unknown due to the
inherent difficulties in linking a phosphorylated substrate to the protein kinase that produced
it. Using the Traceable Kinase Method (Shah et al., 1997), the α6 isotype of α-tubulin was
identified as the novel substrate of PKCα in MCF-10A cells (Abeyweera and Rotenberg,
2007). Furthermore, Ser165 in α6-tubulin was identified as the major site of phosphorylation
by conventional and novel PKC isoforms. By the use of phosphomimetic and
phosphorylation-resistant mutants at Ser165, this residue was shown to be the single major site
in α6-tubulin that is phosphorylated by PKCα (Figure 1.3). Ser165 is embedded in a PKC
consensus site that is present in all eight known α-tubulin isotypes, while being an analogous
segment is absent from other members of the tubulin superfamily. Therefore, all of the native
α-tubulin isotypes can be regarded as potential substrates of PKC. It is presently unknown as
6
	
  

	
  
	
  

Figure 1.3: S165 is the primary site of phosphorylation by PKCα in α6-tubulin. GFP-S165N-α6tubulin suppresses DAG-lactone stimulated phosphorylation of endogenous α-tubulin in MCF10A cells (Abeyweera et al., 2009).

to which isotypes, other than α6-tubulin, are expressed in MCF-10A cells. It is notable that
the α6 isotype is a major α-tubulin isotype detected in metastatic human breast cells such as
MDA-MB-231 cells (Verdier-Pinard et al., 2003).
The assembly and stability of α/β-tubulin heterodimers that comprise protofilaments of
microtubules are critical in cell movement. In the polymerization step, the α6-tubulin of an
incoming heterodimer makes contact with the (+) end β-tubulin by an exchange of GTP and
GDP near the interface of Ser165 of α-tubulin. It was hypothesized (Abeyweera et al., 2009)
that the presence of a negatively charged phosphoryl group at Ser165 in α6-tubulin may
promote polymerization by: (1) facilitating contacts between docking α-tubulin and plus-end
β-tubulin; (2) increasing hydrolysis of GTP to GDP on β-tubulin; or (3) enhancing the
guanine nucleotide exchange factors (GEFs) and activation proteins (GAPs).
To determine the functional significance of α6-tubulin that has undergone phosphorylation by
PKCα, a single site mutation was introduced at each of the potential PKC consensus sites in
α6-tubulin, namely, Ser158, Ser165, Ser241, and Thr337 (Abeyweera et al., 2009). Each residue
was substituted with an Asp residue to simulate the presence of a phosphate group (pseudophosphate). Results showed that amongst other pseudo-phosphorylated constructs of α6tubulin, the S165D mutant was the only one that recapitulated the effect of WT PKCα7
	
  

	
  
	
  

Figure 1.4: (A) Motility assay carried out by transfecting MCF-10A cells with single site-pseudophosphorylated mutants of α6-tubulin. (B) Phosphorylation-resistant mutant S165N-α6-tubulin
inhibits cell motility of MCF-10A cells treated with DAG-lactone (Abeyweera et al., 2009).

induced motility of intrinsically non-motile MCF-10A cells (see Figure 1.4A). For cells
expressing either WT-PKCα or the S165D mutant of α6-tubulin, motility was nocodazolesensitive, thereby confirming that intact microtubules were required for motility. On the
contrary, expression of phosphorylation-resistant mutant S165N-α6-tubulin in stimulated
cells (either expressing PKCα or treated with DAG-lactone) induced suppression of cell
motility (see Figure 1.4B) while impeding the phosphorylation of endogenous α6-tubulin, as
detected by Western blot (Abeyweera et al., 2009). These findings support a model in which
PKCα phosphorylates α6-tubulin at Ser165, thereby enhancing cell motility by MT-mediated
pathways. These mutants (S165D/N) are used extensively in this work to quantitatively
establish the mechanistic role of α-tubulin in cell motility.
In view of a central role in cell migration and division, MTs continue to serve as a target for
cancer therapeutic intervention. Several MT-targeting agents have been designed such that
they modulate MT dynamics. Microtubule targeting agents (MTAs) can be broadly
categorized into two classes, i.e., MT stabilizing and destabilizing drugs. Such drugs bind to
the β-tubulin of the α/β heterodimer, induce structural changes to the MT lattice, and alter
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their functioning during division, proliferation and migration of cancer cells. MT stabilizing
drugs that are used clinically target the ‘taxol’ domain and include: paclitaxel, taxane,
docetaxel, epothilones, peloruside, and sulforophanes. MT destabilizing agents targeted
against ‘vinca’ and ‘colchicine’ domains include nocodazole, vinca alkaloid, colchicine, 2methoxyestradiol (2ME2), and dolestatin. These drugs act either by stabilizing the lateral
interactions between protofilaments, lead to the lengthening of the pause duration by
arresting MT dynamics, or by preventing polymerization of MTs thereby suppressing their
dynamicity (Dhamodharan et al., 1995; Yvon et al., 1999; Pourroy et al., 2006; Kamath et al.,
2006; Chan et al., 2011; Kapoor, 2012; Prudent et al., 2013). Apart from MTAs altering MT
dynamicity in cells, certain post-translational modifications of α-β tubulin can include
acetylation, tyrosination, polyglutamylation, palmitoylation, as well as phosphorylation, and
can affect their behavior in vivo (Fourest-Lieuvin et al., 2006), (Souček et al., 2006)
(Blagosklonny et al., 2002). Currently, there are no reports on the significance of
phosphorylation of α-tubulin and its impact on MT dynamics in breast cancers. The novelty
of this study lies in elucidating the mechanistic role of the PKCα substrate α-tubulin in
conferring enhanced motility in breast cancer cells.

1.6: PKCα, small-G-proteins, and MTs
RhoA, Rac1, and Cdc42 are members of the Rho family of the Ras superfamily of small
GTPases. They play critical roles in regulating the shape, motility and polarization of cells.
Rho-GTPases have been found to interact with and activate proteins such as PKCα, PKN,
PRK, and ROCK, thereby regulating various cellular responses. Slater et al. (2001) showed
that PKCα interacts with RhoA, Cdc42 and Rac1, and that these interactions result in the
activation of PKC. This protein-protein interaction is regulated by Ca+2, phorbol ester and the
GTP/GDP ratio (bound and unbound states of G-proteins). Although Rho-GTPases do not
9
	
  

	
  
	
  

necessarily interact with membrane bound PKCα, not much is known about the direct
interaction of PKCα with Rac1.
Lamellipodial protrusions of migrating cells require continuous actin polymerization. The
small GTPases like Rac1 are known to regulate actin polymerization near cell-leading edges.
In this regard, Rac1 is known to be activated by MTs near cell-leading edges and drive cell
locomotion (Nobes and Hall, 1999; Waterman-Storer et al., 1999). Rac1 and MTs act in a
positive feedback loop where MTs activate Rac1, which eventually promotes further MT
growth. This, along with actin filaments, act in a concerted way to create a local pool of plusend MTs that in turn facilitate cell migration (Fukata et al., 2002; Wittmann et al., 2003).
While engaging in MT capture near the cell periphery, Rac1 associates with membranebound IQGAP.
In the current study, we further investigate the effect of phospho-α-tubulin on membrane
proteins Rac1 and IQGAP, both of which have roles in cell migration.

1.7: MTs and MARCKS
Myristoylated-alanine-rich C kinase substrate (MARCKS) is a PKC substrate that
participates in the mechanism of cell migration. It is known to cross-link with actin, an
activity that is regulated by phosphorylation by PKC. Previous studies with fibroblasts
showed that MARCKS (phosphorylated form, pMARCKS) is associated with the lysosomal
compartment upon treatment with a PKC-activating phorbol ester. Upon removal of the
activator, the dephosphorylated MARCKS was returned to the membrane in a nocodazolesensitive manner, indicating that the recycling process may be linked with MTs (Allen and
Aderem, 1995). Recent experiments conducted in our laboratory have shown that pMARCKS
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once formed by PKCα is released from the plasma membrane to cytoplasm, and from this
location triggers motility of B16 mouse melanoma cells (Chen and Rotenberg, 2010).
In view of our interest in the functional aspects of phospho-α-tubulin, this study will explore
its possible involvement in MARCKS transport.

In addition, the cytoplasmic binding

partners of pMARCKS will be investigated by TAP (Tandem Affinity Purification)
methodology in order to determine their contribution to the motility of human breast cells.

1.8: Outline of the thesis
The thesis is organized as follows. In Chapter 2, we describe the materials and methods used
in the various studies reported. Chapter 3 establishes the mechanistic role of phosphorylated
α6-tubulin in driving live cell microtubule dynamics, and in the distribution of α6-tubulin
into MTs. Studies also consider the impact of α6-tubulin mutants with regard to possible MT
interactions with plasma membrane proteins like Rac1 and IQGAP1 during the process of
cell movement. The link between MARCKS and microtubules in cells expressing α6-tubulin
mutants is investigated in Chapter 4, along with identification of the binding partners of
phospho-MARCKS using a TAP approach. Chapter 5 characterizes the impact of α-tubulin
mutants in normal and malignant breast cells in a three-dimensional growth assay that
simulates the in vivo microenvironment. The significance of these studies is discussed in
Chapter 6.
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Chapter 2: Materials and Methods

2.1: Materials
Human mammary epithelial cells (MCF-10A) were obtained from The Barbara Ann
Karmanos Cancer Center (Detroit, Michigan), and metastatic human breast MDA-MB-231
cells were from the ATCC (Manassas, VA). The bi-cistronic DsRed plasmid was purchased
from Clontech Laboratories (Mountain View, CA), and pIRESneo-EGFP-α-tubulin (human
TUBA1B; #12298) and human EGFP-EB1 (#17234) plasmids were obtained from Addgene
(Cambridge, MA).

Cell culture media, antibiotics, serum, EGF, insulin, DABCO, and

secondary antibodies (FITC-conjugated goat anti-rabbit and Alexa Fluor 594-conjugated goat
anti-mouse) were purchased from Life Technologies (Carlsbad, CA).

HRP-conjugated

secondary antibodies were acquired from Santa Cruz Biotechnology (Santa Cruz, CA).
PolyExpress transfection reagent was obtained from Excellgen, Inc. (Rockville, MD), bisindoleylmaleimide (BIM) from EMD Biosciences (La Jolla, CA), oxyrase from Oxyrase, Inc.
(Ontario, OH), and restriction enzymes were from New England BioLabs (Ipswich, MA).
Hydrocortisone, sodium lactate, protease inhibitors, phosphatase inhibitors, and α-tubulin
antibody (DM1A) were purchased from Sigma-Aldrich (St. Louis, MO). Myc and β-actin
antibodies were purchased from Cell Signaling Technology, Inc. (Beverly, MA). Reagents
for Rac1, Cdc42, and RhoA pull-down assay reagents were obtained from Cytoskeleton, Inc.
(Denver, CO). The Rac1 inhibitor NSC23766 was acquired from Calbiochem-Millipore
Corp. (Billerica, MA). Polylysine-coated 35-mm glass-bottom dishes were purchased from
MatTek (Ashland, MA). DAG-lactone was a gift from V. Marquez (NCI-Frederick).

2.2: Plasmid construction
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2.2.1: Subcloning of myc-tagged α6-tubulin to pCMV4-DsRed vector
Human α6-tubulin (TUBA1C) myc-tagged constructs (wild-type, pseudo-phosphorylated
S165D and phosphorylation-resistant S165N mutants, ~1.56kb) were expressed from a
pCDNA3.1-myc vector (~5.5kb), (Abeyweera et al., 2009) and by a PCR extension method, a
SalI restriction site was introduced near the 3’ end of the myc-α6-tubulin constructs by the
primer 5’ CCGTCGACTCAGGTATGCATATT 3’, followed by in-frame cloning into BamHI
and SalI sites of the pCMV4-DsRed vector (~3.78kb). The entire sequence was verified by
DNA sequencing (Macrogen, Inc., Rockville, MD). At least three clones for each constructs
were selected, expressed in MCF-10A cells, and lysates were immunoprecipitated with antimyc antibody (1:200). The resulting Western blot was probed with mouse monoclonal
DM1A anti-α-tubulin (1:20,000, Sigma) to detect α-tubulin bands near 50-55k Da.

2.2.2: Subcloning of myc-tagged α6-tubulin into the EGFP-N1 vector
Human α6-tubulin (TUBA1C) myc-tagged constructs (pseudo-phosphorylated S165D and
phosphorylation-resistant S165N mutants,~1.56 kb) were expressed from a pCDNA3.1-myc
vector (~5.5kb), and by a PCR extension method, a NotI restriction site was introduced near
the

3’

end

of

the

α6-tubulin-myc

constructs

with

primer

5’

CCGCGGCCGCTCAGGTATGCATATT 3’, followed by in-frame cloning into BamHI and
NotI sites of EGFP-N1 vector (~6.1kb). The entire sequence was verified by DNA
sequencing (Macrogen, Inc., Rockville, MD). At least three clones for each constructs were
selected, expressed in MDA-MB-231 cells and the myc-tagged-α-tubulin proteins (~55kDa)
were detected by a rabbit monoclonal anti-myc and mouse monoclonal DM1A anti-α-tubulin
(1:20,000, Sigma).

2.2.3: Subcloning of D/S and A2G2-N/S MARCKS to TAPA vector
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Bovine GFP tagged D/S and A2G2-N/S MARCKS (~1.086kb) were expressed from a EGFPN1 vector (~4.7kb), and by a PCR extension method, a SalI restriction site was introduced
near

the

3’

end

of

MARCKS-EGFP

constructs

by

the

primer

5’

GGTCGACGGTGGGGCGCTTCTGG 3’, followed by in-frame cloning into HindIII and SalI
sites of the pEGFP-N1 vector (~6.1kb). The entire sequence was verified by DNA
sequencing (Macrogen, Inc., Rockville, MD). At least three clones for each constructs were
selected and expressed in MCF-10A cells. Following Western blotting, MARCKS bands near
80 kDa were detected by a rabbit monoclonal anti-MARCKS (1:1000, Cell Signaling). The
above-mentioned subclones are tabulated in Table 2.1.

2.3: Transformation of bacterial cells and plasmid preparation
Plasmid DNA was diluted to approximately 50 ng/µl. Competent DH5α cells were gently
thawed on ice and 50 µl cells were transferred to a pre-chilled Eppendorf tube. One microliter
of the diluted DNA was added to the bottom of the cells and the mixture was incubated on ice
for 30 min. After subjecting the cells to heat-shock for 45 sec at 42oC, the mixture was
incubated on ice for another 2 min. Pre-warmed (to 37oC) S.O.C medium (0.9 ml) was added
to the mixture and incubated in a water bath shaker for 1 h at 37oC at 200 rpm. The reaction
medium (250 µl) was spread on an agar plate prepared with the appropriate antibiotic. The
plate was incubated in a 37oC incubator for over 16 h. Single colonies were isolated and
cultured for subsequent plasmid preparation. Plasmids were isolated from bacterial cells by
use of the Qiagen Midi-prep kit (Valencia, CA).
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Table 2.1: Plasmids constructed with α6-tubulin and MARCKS used for cell-based experiments.

2.4: Cell culture and transfection
MCF-10A cells were cultured in 10-cm plates (BD Falcon) at 37oC and 5% CO2 in
DMEM:F12 media supplemented with 15% equine serum, insulin (10 µg/ml), epidermal
growth factor (20 ng/ml), cholera toxin (100 ng/ml), and hydrocortisone (0.5 µg/ml), and
maintained with antibiotics [1% penicillin/streptomycin, and fungizone (0.5 µg/ml)] (Soule et
al., 1990). MDA-MB-231 cells were grown in Iscove’s Modified Dulbecco’s medium with
L-glutamine, 10% fetal bovine serum, and antibiotics. Cells were recovered from the plates
by trypsin-EDTA (0.25%) treatment and sub-cultured in a 1:3 ratio every 3–4 days.
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Transient transfections were performed with PolyExpress in a 1:3 (DNA:Polyexpress) ratio,
followed by a 2-day recovery period prior to experimental analysis. At 44-46 hours, the
transfection efficiencies were typically 65-75% (single transfection) and 55-65% (cotransfection). Of the two α6-tubulin mutants, S165D gave higher transfection efficiency (7580%) similar to the wild-type, while the S165N mutant gave typically 60-65%.

2.5: Generation of stable cell lines
MDA-MB-231 cells were transfected with S165D- or S165N-α-tubulin-myc-tagged (8 µg)
and Lipofectamine 2000 (Invitrogen, 12 µl for each well in a 6-well plate). The transfected
cells were selected at 1000 µg/ml G418 (50 mg/ml) for 4-5 days, followed by a gradual
reduction in the strength of the selection drug to 400 µg/ml for an additional 10-12 days.
Cells were replaced with fresh media containing drug every 2 days. At one point there was
massive cell death leaving colonies of stable cells behind. In a day or two, when the wells
were confluent, the cells were trypsinized and transferred to a 6-well plate. Once the clones
were selected, they were grown in 10-cm dishes and maintained at 300 µg/ml of G418 drug.
Protein expression of myc-tagged constructs in stable cells were verified by Western blot
analysis using a rabbit polyclonal anti-myc antibody (1:1000, Cell Signaling Technology),
and by immunocytochemistry using a rabbit monoclonal anti-myc antibody (1:300, Cell
Signaling Technology).

2.6: Western blot analysis with TP4131-phospho-S165-α6-tubulin antibody
Cells transfected with myc-tagged wild-type or S165N-myc-tagged α-tubulin or the empty
vector pcDNA, were treated with DAG-lactone (10 µM) or DMSO (0.05% v/v) for 1 hour
followed by lysis using 1x lysis buffer (Cell Signaling Technologies #9083) containing
1:1000 protease inhibitor cocktail (Sigma), 1:100 phosphatase inhibitor cocktail (Sigma) and
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10 µM bis-indoleyl maleimide (BIM). The samples was each brought up 500 µl with wash
buffer containing 50 mM Tris-HCl, 150 mM NaCl, and 1 mM EGTA along with protease
inhibitors (1:1000), phosphatase inhibitors (1:100) and BIM (1:1000). For the pre-clearing
step, 25 µl rabbit IgG-AC (Santa Cruz Biotechnologies Inc. #2345), and 50 µl of protein A/G
plus-agarose beads (Santa Cruz Biotechnologies, Inc. #2003) were added to each sample and
incubated at 4°C by gentle rotation for ~2 hrs. The pellets were obtained by centrifugation at
10,000 x g at 4°C for 10 min. To the pre-cleared supernatant, monoclonal rabbit anti-myc
antibody (1:200, Cell Signaling #71D10) was added, and immunoprecipitated by gentle
rotation at 4°C overnight.

Protein A/G plus-agarose beads (50 µl of slurry) were added,

rotated for 1 h at 4°C, followed by collection of the pellets by centrifugation at 10,000 x g at
4°C for 10 min. The supernatants were saved for analysis. The collected pellet was washed
twice by gentle resuspension using the wash buffer, followed by gentle rotation at 4°C and
centrifugation. Finally, the pellets (equivalent to 50µl) were reconstituted in 5x sample
loading buffer and wash buffer and boiled at 95°C for 5 min. Samples were resolved in an
8% acrylamide gel. Tubulin bands were detected at 50-55 kDa by phospho-S165-antibody
TP4131 (ECM Biosciences). This antibody was raised against phospho-S165 residue is a
synthetic based on the sequence in α6-tubulin. TP4131 was probed at 1:4000 (overnight), and
its corresponding secondary antibody at 1:20,000. The bands were confirmed by probing with
anti-α-tubulin antibody (1:2000, Epitomics).

2.7: Isolation of MTs and Western Blot analysis
To perform tubulin extraction for isolating soluble and insoluble fractions, MCF-10A cells
were cultured in 6-well Falcon plates and transfected with myc-tagged α6-tubulin constructs
(wildtype or mutants) or the empty vector (control), and processed as previously described
(Vogelsberg-Ragaglia et al., 2000) and (Fourest-Lieuvin et al., 2006). Cells were washed
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with phosphate-buffered saline (PBS) and lysed in pre-warmed (37 °C) high salt RAB buffer
[0.1 M MES (pH 6.8), 0.5 mM Mg2SO4, 1 mM EGTA, and 2 mM dithiothreitol (DTT)]
supplemented with 0.1% Triton X-100, 40 µM Taxol, 2 mM GTP, 10 µM BIM,
serine/threonine phosphatase inhibitors and protease inhibitors (1 mM phenylmethylsulfonyl
fluoride, 10 ng/ml leupeptin, 10 ng/ml soybean trypsin inhibitor). Ultracentrifugation of cell
lysates (Beckman TLA 100.2) for 1 h at 288,000 x g resulted in a soluble fraction
(supernatant) and an insoluble fraction that contained MTs. The pellets were resuspended in
200 µl 1X RAB buffer following brief sonication. Total protein content of each fraction was
determined by colorimetric assay (Bio-Rad). Twenty-five percent of each fraction volume
was resolved by 8% SDS-PAGE followed by immunoblotting with either rabbit monoclonal
anti-myc or mouse monoclonal anti-α-tubulin (DM1A). β-actin antibody was used to judge
equivalent loading of samples from the soluble fractions. HRP-conjugated secondary
antibodies were used for detection by chemiluminescence with West Pico Super Signal
reagents (Pierce Biotechnology). Band intensities were analyzed using Image J software
(version 1.41a).

2.8: Live cell image acquisition and data analysis
To perform live cell imaging, cells were initially grown on 60-mm culture dishes and at 24 h
post-transfection cells were replated into 35-mm polylysine-coated glass-bottom dishes.
Before imaging, the cell growth medium was replaced with phenol-red (PR)-free complete
DMEM/F12 medium containing 15 mM HEPES, 0.6 units/ml oxyrase and 10 mM sodium
lactate (oxyrase substrate) to reduce photo-bleaching and photo-toxicity (Salaycik et al.,
2005). Where indicated, either 10 µM DAG-lactone or DMSO (0.05% v/v) was added to
cells, followed by incubation for 1 h (37oC, 5% CO2) prior to imaging.
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Live cell images were collected using an inverted TCS-SP5 laser-scanning confocal
microscope (Leica Microsystems) with a 63x 1.4NA oil-immersion objective lens. Laser
intensities were kept at 25% and the pinholes were typically set to 1–1.5 Airy units. For timelapse studies, images were acquired at 2-sec intervals at ambient temperature for a total time
of 30-sec from a single Z-plane while applying a 32-line mean average. Images were
analyzed with MetaMorphTM software (Molecular Devices, version 7.7.6) for experiments
with EGFP-α-tubulin, or with Image J software for experiments with EB1-EGFP, as
described below.

2.9: Quantitation methods used for analysis of live cell images

2.9.1: Measurement of MT growth rate and dynamic instability with EGFP-α-tubulin
MT growth and shortening rates were measured by tracking MT ends using the ‘track-point’
function of MetamorphTM linked to an Excel spreadsheet with a customized macro
(Wittmann, 2003). MTs that remained visible for 30 sec and approached the cell periphery
were chosen for analysis. For accurate measurements, a static point in the culture dish was
adopted as a fiduciary mark relative to which the MT ends were analyzed for changes in
length. The lengths of individual MTs were graphed as a function of time (life history plot).
Only MT length changes exceeding the optical resolution limit of 0.1 µm per frame (~3 µm
per min) were considered as growth or shortening events (Wittmann, 2003). Dynamicity was
calculated as the sum of the growth and shortening lengths of MTs divided by the total
observed time.

The percentage of total time that MTs spent growing, shortening or pausing was determined,
as were the transition events from pause or growth to shortening (catastrophes), and from
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shortening to growth (rescues). The catastrophe frequency (or rescue frequency) was defined
as the number of catastrophe events (or rescue events) divided by the time of growth and
pause (or time of shortening).
The average rates of growth, shortening and dynamicity were presented as the mean ± 1 s.d.
A minimum of 40 MTs were analyzed for each condition over three independent
experiments. The remaining dynamic parameters (i.e. percentage time spent growing,
shortening, or pausing, and frequencies of catastrophes and rescues) are defined on the basis
of the entire life history of all MTs for the indicated condition on a given day. Due to the 30sec observation time constraint imposed by photo-bleaching, these parameters were not all
attainable for individual MTs, especially the relatively low frequency of rescue. As a result,
the percentages were calculated on an aggregate basis (Kamath et al., 2006) from each
independent experiment and presented as the mean ±1 s.d. of three independent experiments
conducted on different days. Since very few rescue and catastrophe events were observed for
a single experiment, these quantities were reported on an aggregate basis over all three
experiments. Events observed fewer than 10 times were not reported.

2.9.2: Quantitation of EB1-EGFP comets in live cells
The peripheral regions of MCF-10A cells, treated with 10 µM DAG-lactone or 0.05% DMSO
(v/v) (1 h, 37oC) were sub-divided into regions of known dimension by Image J. The number
of EB1-EGFP comets in each region was counted manually and the average number of
signals per unit area (µm2) was determined.

2.10: Immunofluorescence, image acquisition and data analysis
MCF-10A cells grown on glass-coverslips were transfected with the indicated plasmid(s) and
maintained as described above. Following DAG-lactone (10 µM) or DMSO (0.05 % v/v)
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treatment for 1 h, cells were fixed in 4% paraformaldehyde (PFA) at room temperature for 10
min. Coverslips were incubated for 30-sec in microtubule-stabilizing and extraction (MSE)
buffer (80 mM PIPES, 1 mM MgCl2, 4 mM EGTA, 0.5% Triton X-100), followed by
washing with PBS and incubation in immunoblocker (2% BSA, 0.1% sodium azide) for 15
min at 37oC.

Fixation followed by permeabilization and extraction was found to give

consistently high imaging quality with these cells. After blocking, cells were incubated
overnight at 4oC with mouse monoclonal DM1A anti-α-tubulin (1:300) and rabbit
monoclonal anti-myc (1:200) followed by FITC-conjugated goat anti-rabbit (green, 1:300)
and Alexa Fluor 594-conjugated goat anti-mouse secondary antibodies (red, 1:300). Cells
were mounted on clean glass slides with DABCO and sealed. Images were captured by a
Plan-Neofluar 100 X or 63x 1.4NA oil immersion objective lens using an Axio Imager-M2
upright fluorescence microscope (Zeiss).

2.10.1: Co-localization data analysis
For measuring co-localization of myc-tagged α6-tubulin with endogenous MTs in MCF-10A
cells, the red and green signal intensities of individual cells were analyzed by Pearson’s index
with Image J software (Bolte and Cordelieres, 2006). Pearson’s index (rp) is a normalized
cross correlation coefficient between two channels (red and green), and is averaged across the
total number of pixels. The resulting rp value falls within a range of -1 (complete exclusion)
to 1 (complete co-localization). Let the intensities of channel A and channel B in the ith pixel
be denoted Ai and Bi, respectively. Letting a and b correspond to the average intensities over
the full image gives:

21
	
  

	
  
	
  

To quantify the myc signals (green) for α6-tubulin at the cell periphery, Image J was used to
analyze images digitally with 160 µm2 boxes at 2-3 places along the leading edge of a cell,
and the average intensities were determined for three independent experiments.

2.10.2: Gamma-tubulin staining
For gamma tubulin experiments, MCF-10A cells were treated for 1 h with DAG-lactone (10
µM) or DMSO (0.05% v/v) before fixing with ice-cold methanol at -20oC for 5 min. Cells
were permeabilized in 1x MSE buffer for 30 s followed by washing in PHEM buffer (60 mM
PIPES, 25 mM HEPES, 10 mM EGTA and 2 mM MgCl2, pH 6.9) three times. After
blocking, the cells were incubated overnight at 4oC with mouse gamma tubulin antibody
(1:1000; Sigma) followed by Alexa Fluor 594-conjugated goat anti-mouse (Invitrogen)
secondary antibody (1:300). DNA was labeled with Hoechst 33342 stain (Invitrogen, 1:1000)
for 15 min at 37oC before mounting. Images were captured by a Plan-Neofluar 100 X oil
immersion objective lens using the Axio Imager-M2 upright fluorescence microscope (Zeiss).

2.10.3: Rac1, IQGAP and E-cadherin staining
Cells treated with DAG-lactone or expressing either S165D- and S165N-α-tubulin were
analyzed for the localization of Rac1, IQGAP, or E-cadherin. Cells were extracted with MSE
buffer for 30 s, washed three times with PHEM buffer or 1X PBS, and blocked at 37oC for 15
min. For experiments pertaining to the inhibition of Rac1, cells (parental or S165D) were
incubated with the inhibitor (75 µM) alone for at least 5-6 h and then with DAG-lactone (or
DMSO) for an additional hour (without removing the inhibitor from the medium). Cells were
fixed for 15 min in 4% PFA. Depending on the purpose of experiment, cells were stained
with Rac1 antibody (1:20), mouse monoclonal anti-myc (1:300, Cell Signaling Technologies,
Inc.), rabbit monoclonal anti-IQGAP (1:200, Epitomics), or mouse monoclonal anti-E22
	
  

	
  
	
  

Cadherin (1:100, Santa Cruz) overnight, followed by FITC-conjugated goat anti-rabbit
(green, 1:300) or Alexa Fluor 594-conjugated goat anti-mouse secondary antibodies (red,
1:300). In some cases, rhodamine phalloidin (1:300) and Hoechst 33342 (1:1000) were used
to stain actin filaments and nuclei, respectively. Cells were mounted on clean glass slides
with DABCO and sealed. Images were acquired by a 63x1.4NA or a 100X oil immersion
objective lens using the Axio Imager-M2 upright fluorescence microscope (Zeiss).

2.10.4: Membrane staining
Fixed cells on glass coverslips (by following the protocol mentioned above) were stained
with 2.5 µg/ml of Cell Mask Membrane stain (Invitrogen) in 1X PBS, for 15 min at 37oC
followed by washes in 1x PBS three times and mounting on glass slides.

2.11: MARCKS distribution and quantitation in MCF-10A cells
Sub-cellular MARCKS distribution was measured in MCF-10A cells expressing WT-GFPMARCKS and either the S165D or S165N mutant of α6-tubulin expressed from a DsRed
plasmid. Forty-eight h after transfection, the cells were fixed in 3.7% paraformaldehyde and
0.5% gluataraldehyde for 10 min at room temperature (Ouimet et al., 1990) and (Spizz and
Blackshear, 2001). Fixation was followed by quenching of unreacted glutaraldehyde for 1015 min with 5 mM NH4Cl (in 1M Tris buffer pH 7.4) and 0.1 % NaBH4 in PBS. After
subsequent washes with PBS, cells were extracted for 30 sec with MSE buffer, washed three
times in PBS and mounted with DABCO on glass slides. Fixed cells expressing both EGFP
and DsRed fluorescence were selected for analysis.

Images were recorded at ambient

temperature using by fluorescence microscopy. Fluorescence intensities were quantified by
Image J software.
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To measure GFP-MARCKS sub-cellular distribution, the signal intensities (green) were
calculated using Image J near the cell periphery or in the interior region of cells by selecting
each of these regions and measuring the average fluorescence intensity per pixel (Lecuona et
al., 2009). Reported intensities were obtained by averaging the values of approximately
twenty cells for each condition.

2.12: Measurement of MT plus-ends with EB1-EGFP in MCF-10A cells
Experiments were conducted with MCF-10A cells in which MTs were eliminated by
nocodazole (NOC) treatment and analyzed at different time points for the appearance of
nascent MTs after NOC removal. At 42-44 h post-transfection with EB1-EGFP, cells were
treated with 6.6 µM NOC for 5 h at 37oC to eliminate all microtubules. Following NOC
treatment, cells were rinsed once with PHEM buffer [60 mM piperazine-N, N’-bis (2ethanesulfonic acid), 25 mM HEPES, pH 6.9, 10 mM EGTA, and 4 mM Mg2SO4], treated at
t=0 with either DAG-lactone (10 µM) or DMSO (0.05% v/v), and fixed at the indicated times
for 5-10 min in ice-cold methanol (-20oC) (Tulu et al., 2006). The samples were incubated in
1X MSE buffer for 30-sec and washed three times with PHEM buffer before mounting.
Imaging was performed by fluorescence microscopy. EB1 signals were counted by the
particle detector program of Image J (Gusnowski and Srayko, 2011). Threshold values were
selected that maximized the number of EB1-GFP comets in each cell (the object size adjusted
to a radius of 3-pixels), and the circularity setting was optimized. At least 18 cells from
different time points of each treatment were used for quantitation. Results are reported as an
average number of EB1 signals from three independent experiments.

2.13: Pull-down assay of activated small GTPases
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Activation of small GTPases was measured in lysates of MCF-10A cells using commercially
available buffers (Cytoskeleton, Inc.).

Briefly, cells (transfected with either S165D- or

S165N-α6-tubulin) were disrupted in a lysis buffer (50 mM TRIS, pH 7.5, 10 mM MgCl2, 0.5
M NaCl, 2% Igepal) supplemented with phosphatase and protease inhibitors followed by
centrifugation at 13,000 x g at 4 °C for 10 min. Agarose beads conjugated to either PAKbinding domain (PBD) (Millipore Corp.) or Rho-binding domain (RBD) (Cytoskeleton, Inc.)
were used in a pull-down assay to isolated activated G-proteins. Cell lysates with a total
protein content of 600 µg of protein were incubated with PAK-PBD beads (10 µg) or RBD
(25 µg) beads at 4°C for 1h. The beads were washed once with wash buffer (25 mM TRIS,
pH 7.5, 30 mM MgCl2 and 40 mM NaCl) followed by centrifugation at 4°C. The entire
sample was loaded and the bound proteins were separated by 12% SDS-PAGE and
immunoblotted with anti-Rac or anti-Cdc42 (Cell Signaling Technology), or anti-RhoA
(Cytoskeleton, Inc.).

2.14: Motility assay
MCF-10A cells were plated onto a 10-well slide through a cell sedimentation manifold
(CSM, Inc., Phoenix, AZ) as concentric circles followed by incubation at 37oC and 5% CO2.
After removal of the manifold (t=0), images were recorded with a camera attached to an
inverted Nikon Diaphot microscope. After 16 hours, during which cells radiated outwardly,
images were taken again and motility was calculated by the change in total area (in µm2)
occupied by the cells (Motic Image Plus 2.0). Each reported value is the average of triplicate
measurements.

2.15: Tandem affinity purification (TAP) method
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The TAP method involves purification of a protein complex under non-detergent conditions
by two affinity columns (streptavidin and calmodulin affinity resins) and the resulting eluate
is analyzed by SDS-PAGE and analyzed by mass spectrometry. This experiment was carried
out by following the manufacturer’s protocol (InterPlay Mammalian TAP system; Agilent).
Briefly, the cells were transfected with pCTAP vector containing a MARCKS construct. This
vector contains a calmodulin binding peptide (CBP) and a streptavidin binding peptide (SBP)
sequence near the C-terminus of the gene of interest. These two affinity purification tags
enable isolation of the protein complex by gentle washing and elution method without
disrupting the targeted complex.
At 44-48 hrs post-transfection, the cells were resuspended in lysis buffer supplemented with a
cocktail of protease inhibitors (1:100, Sigma), phosphatase inhibitors (1:100, Sigma) and
lysed by an alternate freeze (dry ice) and thaw (cold water) intervals four times, 15 min for
each condition. Lysis was followed by centrifugation of the mixture at 16,000 x g for 10 min
to collect the pellets which were discarded. The remaining supernatant was incubated with
streptavidin resin (50 µl resin for 1x107 cells) pre-calibrated with 1 ml streptavidin binding
buffer [0.5M EDTA, 10 mM β-mercaptoethanol] and rotated gently for 2 h at 4oC. The resins
were collected by centrifugation at 1500 x g for 5 min, and resuspended in 1ml of
streptavidin binding buffer, rotated at 4oC for 5 min followed by centrifugation at 1500 x g
for 5 min. By this method, the resins were washed to remove any proteins bound nonspecifically to the SBP tag or to the proteins directly attached to the resin. To the washed
resins, approximately 100 µl of streptavidin elution buffer was added, followed by rotation at
4oC for 45 min to elute the protein complexes. Following centrifugation, the supernatant
containing the eluted proteins were collected and subjected to a second round of affinity tag
purification on the calmodulin resin. Intermittent supernatants were stored for possible
analysis at -150 oC.
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To the recovered supernatant from the first round of affinity purification using the
streptavidin tag, around 400 µl of calmodulin binding buffer along with 2 µl streptavidin
supernatant supplement was added. Meanwhile the calmodulin resin was prepared. Twentyfive percent of the resin slurry was centrifuged at 1500 x g to collect the resin which was
washed once with 1 ml of calmodulin binding buffer, and resuspended in 12.5 µl buffer
before adding it to the eluted protein solution prepared for this purpose. Eluates containing
the proteins were allowed to bind to the calmodulin resin for an additional 2-3 h by gentle
rotation at 4oC. The pellets were subsequently recovered by centrifugation at 1500 x g for 510 min. The beads were washed with calmodulin binding/wash buffer by rotating the slurry
containing the beads at 4oC for 5 min followed by centrifugation at 1500 x g for an additional
5 min. Finally, after discarding the supernatant, the beads attached to the protein(s) of interest
were reconstituted in 1X loading buffer and boiled at 95oC for 5 min. The supernatant
contained the tandem affinity purified protein complexes that were subjected to an SDSPAGE gel (0.75 mm), the gel was stained with Coommassie Blue, and bands of interest were
excised for mass-spectrometry analysis.

2.16: Three-dimensional cell culture
MCF-10A or MDA-MB-231 cells were cultured in Growth Factor Reduced MatrigelTM from
BD Biosciences (BD#354230, San Jose, CA) on 96-well plastic tissue culture plates
following the overlay three dimensional culture protocol (Debnath et al., 2003). Briefly, each
well of culture dish was pre-coated with ~45 µl Matrigel (96-well plate) or 60 µl (16-well
plate) and allowed to solidify at 37C for at least 30 min. Cells grown to 80% confluence were
trypsinized, resuspended in 1.5 ml of 2% Reduced Serum Assay Medium supplemented with
Matrigel (2%) such that the final seeding density was 3x103 cells/well for round 3D
morphology (MCF-10A cells) and ~2-2.5x103 for stellate 3D morphology (MDA-MB-231
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cells). Once plated, the cell cultures were maintained at 37°C for up to ~10-12 days and refed
with assay medium containing 2% Matrigel every 2-3 days. Bright field images of the
morphology were acquired every 2 days by 10x objective and the images were analyzed by
Image J. MCF-10A cells began forming clusters by Day 5 followed by a gradual formation
of hollow luminal 3D acini-like structures.

2.16.1: Indirect immunofluorescence of 3D acini cultured in matrigel
Usually the immunofluorescence staining was carried out on the 8th day (MDA-MB-231
cells) and 12th day (MCF-10A cells) of culture in Matrigel. After removing the medium,
cells were either isolated from the glass wells after washing three times with ice-cold PBS
supplemented with 100 mM glycine, or fixed directly on 16-well glass slides with 4% PFA
(in PBS, pH 7.4) for 20 min at room temperature (Lee et al., 2007) and (Debnath et al., 2003).
After washing three times with 1X PBS, staining with Hoechst nucleus stain (1:1000 in PBS)
for 15 min, additional washing and mounting with DABCO. Slides were stored at 4oC in dark
and imaged later with the confocal microscope (Leica Microsystems). The number of nuclei
per acinus for each condition was counted by either “analyze particles” or “3D object counter
functions” in ImageJ software (version 1.41a). A central section (z-axis) of each acinus was
chosen for this analysis such that it captured the maximum number of nuclei.

2.17: Statistical analysis
Each experiment was performed a minimum of three times and differences between groups
were determined using the unpaired Student’s t test. The data were evaluated as the mean ±1
s.d. (standard deviation).
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Chapter 3: Phospho-α-Tubulin and the Mechanism of
Motility of Human Breast Cells

3.1: Phosphorylation of α-tubulin by protein kinase C stimulates microtubule dynamics
in human breast cells

3.1.1: Introduction
Microtubules (MTs) are cytoskeletal polymeric structures that are assembled from
heterodimers of α- and β-tubulin proteins (Draber and Draberova, 2012). They originate at
microtubule organizing centers (MTOCs) and continue to grow towards the cell periphery,
during which they undergo frequent episodes of alternating growth and shortening termed
‘dynamic instability’ (Desai and Mitchison, 1997) and (Komarova et al., 2002). Several
parameters used to characterize MT dynamic instability include the rates of growth and
shortening that together define dynamicity, and the frequency of transitioning between the
two phases termed ‘catastrophe’ and ‘rescue’ (Dhamodharan et al., 1995). The term
‘dynamicity’ is defined as the sum of the absolute values for growth and shortening distances
divided by the total observed time. The complexity entailed in MT instability is essential to
the biological functions that MTs perform during cell division, migration, and intracellular
trafficking (Piehl and Cassimeris, 2003); and (Etienne-Manneville, 2013).
The dynamic parameters that define the behavior of MTs have been used to characterize the
mechanism of action of several MT-directed anti-mitotic drugs (Kamath et al., 2006); and
(Chan et al., 2011). MT stabilizing drugs include paclitaxel (Taxol), which increases the net
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polymer mass of MTs in cells by increasing the ratio of MT-incorporated (insoluble)
tubulin:monomeric (soluble) tubulin to 90:10. Destabilizing drugs such as nocodazole or
vinblastine either inhibit MT formation, or depolymerize existing polymers (Dhamodharan et
al., 1995); and (Yvon et al., 1999).

Certain post-translational modifications, such as

acetylation of α-tubulin (Lys-40), also result in altered dynamic behavior of MTs (Azarenko
et al., 2008). Although β-tubulin phosphorylation by Cdk1 during mitosis was previously
reported (Fourest-Lieuvin et al., 2006), no studies have yet addressed whether
phosphorylation of α-tubulin subunits plays a role in the functional behavior of MTs.
Protein kinase C (PKC) is a serine/threonine protein kinase that is known to regulate the actin
cytoskeleton (Larsson, 2006), and is an important factor in breast cancer development (Lonne
et al., 2010). PKC exists as a family of structurally-related isoforms that are defined by the
mechanism of their activation in the cell (Steinberg, 2008). Non-motile, non-transformed
MCF-10A human breast cells contain very low levels of PKC isoforms, especially PKCα,
and therefore provide an ideal environment for identifying PKC substrates. Our previous
studies showed that both over-expression of PKCα in MCF-10A cells and treatment with
DAG-lactone individually resulted in an aggressive cell movement (Sun and Rotenberg,
1999; Abeyweera et al., 2009). A reagent commonly used in our studies is DAG-lactone, a
cell-permeable analogue that selectively activates PKCα, and, to a lesser degree, other DAGstimulated PKC isoforms (Garcia-Bermejo et al., 2002). By applying the traceable kinase
method with MCF-10A cells (Abeyweera and Rotenberg, 2007), it was shown that α6-tubulin
is a PKC substrate that undergoes phosphorylation at Ser-165 in response to DAG-lactone
treatment (Abeyweera et al., 2009). Mutation of Ser-165 to the pseudo-phosphorylated
mutant (S165D-α6-tubulin), followed by its expression in MCF-10A cells, gave rise to cell
motility that recapitulated the effect on these cells of either PKCα overexpression or DAGlactone treatment. Furthermore, phosphorylation of α6-tubulin in cells treated with DAG30
	
  

	
  
	
  

lactone could be almost entirely blocked by either treatment with a pan-PKC inhibitor (bisindoleylmaleimide; BIM), or expression of a site-specific mutant of α6-tubulin that was
resistant to phosphorylation (Ser-165 replaced with Asn; S165N) (Abeyweera et al., 2009).
The physiological significance of phospho-Ser-165 in α-tubulin was also demonstrated with
human breast tumor cells that express intrinsically high levels of PKC (e.g. MDA-MB-231,
MDA-MB-468), and therefore did not require activation with DAG-lactone. The intrinsic
motility of these metastatic cells was significantly inhibited (by 60-75%) following
expression of phosphorylation-resistant S165N-α6-tubulin or treatment with BIM, and
correlated with elimination of endogenous phospho-α-tubulin under these conditions.
Taken together, the previous findings implicate Ser-165 in α6-tubulin as a functionally
significant phosphorylation site recognized by DAG-sensitive PKC isoforms that promotes
cell movement. However, the mechanistic pathway that contributes to this phenotype in
breast cells is not known.
The prevailing hypothesis is that the phosphorylation state of Ser-165 in α-tubulin regulates
motility by altering the dynamic properties of MTs in MCF-10A cells. Therefore, the present
study investigates the effects of Ser-165 mutants or DAG-stimulated phosphorylation of
wildtype (WT)-α-tubulin on the dynamic behavior and stability of MTs, and explores
whether this behavior is perturbed in metastatic human breast cells. In addition, interactions
of elongating MTs with peripheral membrane proteins of known involvement in cell
migration are studied as possible downstream signaling components.

3.1.2: Results
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3.1.2.1: Quantitation of DAG-lactone-induced MT dynamics with EGFP-α-tubulin in
MCF-10A cells
DAG-lactone, a cell permeable PKC activator, was employed to produce phosphorylated αtubulin via activation of endogenous PKC, and the consequential impact on dynamic
behavior of MTs infiltrating the leading edges was investigated. Experiments were performed
with live MCF-10A cells that had been transiently transfected with human EGFP-α-tubulin
(TUBA1B; Kα1) in order to produce uniformly fluorescent MTs and analyze their advancing
and receding movements. Cells that expressed a moderate level of EGFP-α-tubulin
fluorescence were selected for the time-lapse confocal microscopy. For measuring MT
dynamic parameters, plus-ends of MTs arriving at the cell periphery were tracked for around
30 sec, and changes in MT length were plotted against time to generate life history plots for
an individual MT.
A comparison of the life history plots of three representative MTs from control and DAGlactone-treated cells (see Figure 3.1A) illustrates certain key responses by MTs to the
presence of DAG-lactone. Control cells exhibited sedentary behavior having prolonged
pauses, while cells treated with the PKC activator displayed longer intervals of growth
interrupted by shortening phases.
The measurements indicated that MTs display increased rates of growth (see Figure 3.1B),
which enable them to exhibit continuous growth to the cell margin. This response, alongside
with shorter pause duration, contributes to an enhanced dynamicity. A notable observation
was that MTs in lamellipodia tend to be longer and curved in DAG-lactone-treated cells,
indicating a reversal in direction upon contact with the cell periphery (inset in Figure 3.1C).
This phenomenon suggests that DAG-lactone treatment promotes increased longevity of MTs
(Chan et al., 2011).
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Figure 3.1: Fluorescent live cell imaging of MT dynamics in MCF-10A cells expressing EGFP-αtubulin. Transfectants were treated with either 10 µM DAG-lactone (DAG) or DMSO as vehicle
control (0.05% v/v) for 1 h at 37oC and 5% CO2 prior to imaging at 2s interval for a total time of
30s (as described in the Methods) (A) Life history plots of the growing ends of three representative
MTs in these cells treated with or without DAG-lactone. (B) Quantitation of life history plots of
MTs show that treatment with 10 µM DAG-lactone (DAG) increases the dynamicity of MTs (n =
54) in these cells. Statistical significance was determined by the Student’s t-test (*, p<0.0001). (C)
A representative cell expressing EGFP-α-tubulin shows that following DAG-lactone treatment,
growing MTs reverse direction upon contact with the cell periphery (inset). All results are
representative of three independent experiments. Bar, 10 µm.
	
  

Table 3.1 presents the results of extensive quantitation of life history plots for 42-62 MTs of
the kind shown in Figure 3.1A. Compared with control cells, DAG-lactone treatment gave
rise to an overall 2-fold higher dynamicity due to shifts in those parameters that favored net
growth (see Figure 3.1B). The most pronounced effect of DAG-lactone treatment of cells
was a 3-fold increase in the duration of MT growth with shorter periods spent either
shortening or pausing. Moreover, MTs were growing at a 1.4-fold higher rate while the
frequency of catastrophe was decreased by 2-fold. In contrast, MTs in control cells, either	
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Table 3.1: Dynamic parameters of MTs in non-transformed human breast cells. MCF-10A cells
expressing EGFP-α-tubulin were treated with DAG-lactone (10 µM) or DMSO (0.05% v/v) for 1 h
at 37oC, or co-transfected with a plasmid (DsRed) expressing a mutant of α6-tubulin
(S165D/S165N) or the vector control (VC). Values are the mean ± 1 s.d. except for percentages
that represent the entire observed population of MTs. NS, not significant (fewer than 10 events
observed for all MTs). Statistical significance relative to the appropriate control (DMSO or vector
control,VC) was determined by the Student’s t-test: (a) p<0.0001, (b) p<0.001, (c) p<0.01, (d)
p<0.05 and (e) p<0.1. For all t-test calculations, n = total number of MTs was used except for
percentages for growth/shortening/pause where n = 3 was used, corresponding to the number of
independent experiments (as described in the ‘Methods’).

DMSO-treated or untreated parental cells spent more than half the observed time in a paused
state that corresponded to decreased dynamicity, as represented in Figure 3.1B. This
sedentary feature of MTs is consistent with the non-motile behavior of MCF-10A cells (Sun
and Rotenberg, 1999).
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3.1.2.2: Site-specific mutations in Ser-165 of α6-tubulin modulate MT dynamics of
MCF-10A cells
Previous findings from this laboratory identified Ser-165 as the site in α6-tubulin (TUBA1C)
that undergoes phosphorylation by PKC in DAG-lactone-activated MCF-10A cells, and is coincident with the acquisition of motility (Abeyweera et al., 2009). As shown in the earlier
study, non-motile MCF-10A cells also acquired this phenotype with a pseudo-phosphorylated
α6-tubulin that had been mutated at Ser-165 [Ser165àAsp (D)], thereby recapitulating the
outcome produced by PKC activation. In contrast, the motility phenotype was not observed
when MCF-10A cells expressed the phosphorylation-site resistant mutant [Ser165àAsn (N)]
of α6-tubulin. In order to establish that phosphorylation of Ser-165 directly impacts MT
dynamic behavior, live cell imaging was performed with these mutants of α6-tubulin. For
this purpose, each myc-tagged mutant was subcloned from a pcDNA-myc vector into a bicistronic pBI-CMV4-DsRed plasmid that co-expressed DsRed and the mutant as separate
proteins. At least three subclones from each condition were selected, transfected into MCF10A cells, immunoprecipitated with a myc-tagged antibody, and Western blot analysis with a
α-tubulin antibody (DM1A) to confirm the expression of the myc-tagged tubulin proteins
(wild-type or mutants). Figure 3.2 shows the western blot results of the clones (wild-type,
S165D and S165N-α6-tubulin) expressed as separate proteins in DsRed plasmids in MCF10A cells (Methods).
The use of a bi-cistronic vector enabled fluorescence detection of those cells that were
successfully transfected with either the wildtype or each mutant and therefore circumvented
the need for a large fluorescent fusion protein of α6-tubulin. Cells were transfected with this
bi-cistronic vector along with the vector encoding EGFP-α-tubulin so as to uniformly label
MTs. Time-lapse studies of MT dynamics were performed on individual MCF-10A cells that
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Figure 3.2: Western blot showing wild type (WT), and the mutants – pseudo-phosphorylated
(S165D) or phospho-resistant (S165N), of α6-tubulin expressed from a DsRed vector in MCF-10A
cells. Wild type or the mutants of α6-tubulin were subcloned from a pcDNA-myc vector to the
DsRed plasmid by an extension PCR method, introducing a SalI restriction site near the 3’ end of
the myc-tag (see Method section). Atleast three subclones from each condition were confirmed by
restriction digestion (BamHI/SalI), expressed in MCF-10A cells by transfecting with Polyexpress
[1:3 ratio, DNA (µg):Reagent (µl)]. Lysates were subjected to an overnight IP with myc-antibody
(1:200), followed by detection of the α-tubulin bands near 50 kDa by DM1Aα-tubulin antibody
(1:10,000). Clones 12.1 of WT (lane 2) 2 of S165D and 32 of S165N were used for subsequent
experiments. Bands near 50kDa confirmed the successful subcloning of the tubulin genes (Wild
type and mutants) and their corresponding expressions in MCF-10A cells.

expressed both DsRed and EGFP signals, and dynamic parameters of MTs were determined
for each α6-tubulin mutant in comparison with the empty vector (Table 3.1).
As was observed with DAG-lactone-treated MCF-10A cells, MTs in cells that expressed
S165D-α6-tubulin showed a significantly higher dynamicity as compared with the S165N
mutant or cells that received the empty vector (Table 3.11). This effect was dominated by a
longer duration of the growth phase (by 2-fold) (Figure 3.3) and a higher growth rate (by 1.3fold) coupled with a decreased frequency of catastrophe and reduced pause durations. In cells
expressing the phosphorylation-resistant S165N mutant, the percentage of time MTs spent in
growing was unchanged from values obtained for the vector control (Figure 3.3) but was
associated with an increased frequency of catastrophe (Table 3.11) and prolonged pauses.
Altogether, these behavioral changes of MTs suggest that the enhanced motility of MCF-10A
cells upon expressing S165D-mutants resulted from the increased longevity of MTs.
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It is apparent that the expression of S165D-α6-tubulin evoked quantitatively similar
responses from MTs as those induced by DAG-lactone, while the S165N mutant caused only
minor variation to the basal values of untreated MCF-10A cells. Furthermore, the impact of
S165D-α6-tubulin on the duration of growth (62%) is significantly less than the DAG-lactone
effect on this parameter (77%) (see Table 3.11). This finding suggests that, although
phosphorylation of α-tubulin accounts for 80% of the DAG-lactone effect on this parameter,
there are additional PKC substrates, presently unknown, whose phosphorylation via DAGlactone stimulation may further contribute to this property.

3.1.2.3: Phosphorylation of α6-tubulin impacts MT dynamicity in triple-negative
metastatic breast epithelial cells (MDA-MB-231 cells)
The estrogen-progesterone-EGF-independent (triple negative) MDA-MB-231 human breast
cancer cell line is highly invasive and expresses high endogenous levels of active PKC
isoforms of which PKCα is the most abundant (Gauthier et al., 2003). Down-regulation or
inhibition of PKCα in MDA-MB-231 cells results in suppressed proliferation and migration
(Lonne et al., 2010). Because expression of S165N-α6-tubulin was found to inhibit the
intrinsic motility of these cells by 60% (Abeyweera et al., 2009), it was of interest to compare
MT dynamic parameters in MDA-MB-231 cells with those values found for nontransformed, non-motile MCF-10A cells.
Table 3.2 displays the quantitation of life history plots of MTs observed in MDA-MB-231
cells. In these highly motile cells, MTs spent more than 60% of their lifetime in the growth
phase. The dynamic behavior exhibited by these MTs was characterized by random MT
movements near the cell periphery, followed by sudden catastrophe and steep shortening
intervals (plot not shown). It is notable that the chaotic behavior of MTs in these cells
contrasted with DAG-lactone-treated MCF-10A cells in which MTs were more uniformly
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Table 3.2: Dynamic parameters of MTs in metastatic human breast cells. MDA-MB-231 cells
expressing EGFP-α-tubulin were treated with BIM (10 µM) or DMSO (0.05% v/v) for 1 h at 37oC,
or transfected with a plasmid (DsRed) expressing a mutant of α6-tubulin (S165D/S165N) or the
vector control (VC). Values represent the mean ± 1 s.d. NS, not significant (fewer than 10 events
observed for all MTs). Statistical significance relative to the appropriate control (DMSO or vector
control,VC) was determined by the Student’s t-test: (a) p<0.0001, (b) p<0.001, (c) p< 0.01, (d)
p<0.05 and (e) p<0.1. For all t-test calculations, n = total number of MTs except for percentages
for growth/shortening/pause where n = 3 (n = number of independent experiments).

polarized even under conditions in which the dynamic parameters of the two cell types had
comparable values.
Analysis of phosphorylation site mutants of α6-tubulin in MDA-MB-231 cells (Table 3.2)
showed that the phosphorylation-resistant S165N mutant substantially decreased the rates and
duration of growth of MTs (Figure 3.3) and produced prolonged pause intervals. It was noted
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Figure 3.3: Phosphorylation or pseudo-phosphorylation of α6-tubulin increases the fraction of the
total time that MTs spend in the growth phase. Phosphorylation-site mutants of α6-tubulin
(S165D) increase the percentage time that MTs spent growing (positive values) and decrease the
time spent shrinking (negative values) in non-motile MCF-10A (solid bars) and metastatic human
breast MDA-MB-231 (stippled bars) cells. Cells were transfected with DsRed plasmids encoding
the S165D or S165N mutants of α6-tubulin, or the empty DsRed vector control (VC), and their
impact was determined by live-cell imaging followed by quantitation, as described in ‘Methods’.
Addition of 10 µM DAG-lactone (DAG) to MCF-10A cells or 10 µM BIM to MDA-MB-231 cells
was compared with their respective vehicle control (DMSO, 0.05% v/v). The results are based on
a total of 42-62 MTs examined for each condition divided by the total time MTs spent growing or
shortening. Statistical significance was evaluated by the Student’s t-test (*, p<0.1; **, p<0.05;
***, p<0.01; ****, p<0.0001).

that treatment of MDA-MB-231 cells with the PKC inhibitor BIM produced the same
direction of change in these parameters, and was as effective as the phosphorylation-resistant
mutant in decreasing the overall dynamicity. Accordingly, the altered rates and duration of
growth and shortening collectively led to slower growing MTs, similar to control MCF-10A
cells.
In contrast with MCF-10A cells, more modest effects were associated with the expression of
the S165D mutant in MDA-MB-231 cells, such as only a 10% increase in the duration of the
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growth phase. Since MDA-MB-231 cells are intrinsically motile and express abundant levels
of PKCα, the muted impact by the pseudo-phosphorylated mutant is consistent with α-tubulin
that is already highly phosphorylated at Ser-165, presumably due to endogenously active
PKC. By comparing the duration of growth and shortening or pause intervals associated with
each mutant or treatment, it was concluded that for both MCF-10A cells and MDA-MB-231
cells, the duration of the growth phase was the most responsive parameter to the
phosphorylation state of Ser-165. In Figure 3.3, this parameter is used as the basis for
comparing the two cell lines and reveals the impact by phosphorylation or its inhibition.

3.1.2.4: Phosphorylation of α-tubulin promotes partitioning into MTs
A central question that was addressed next was whether site-specific phosphorylation
facilitates the incorporation of α6-tubulin into endogenous growing MTs. Ideally this is
addressed by conducting a fractionation assay of MTs and determining the distribution
pattern of myc-tagged α6-tubulin between intact MTs (polymers or insoluble fraction) and
unincorporated α-tubulin monomers (soluble fraction).	
   Some initial experiments were
conducted with an antibody that was raised against the phosphorylation state of Ser-165residue of α6-tubulin (TP4131, ECM Biosciences). To test the specificity of the antibody,
whole cell lysates were prepared from MCF-10A cells that had been transfected with either
the myc-tagged wildtype (WT), S165N-mutant α6-tubulin or the vector control. Prior to lysis,
the transfected cells were treated with DAG-lactone to activate the PKC-pathway and to
generate phospho-α6-tubulin. Following an overnight IP with a myc-tagged antibody (1:200),
the phospho-α-tubulin bands were detected by the TP4131-P-S165 antibody (see Figure 3.4).
Compared to the control, WTs generated more phospho-α-tubulin upon treatment with DAGlactone as detected by the P-S165-specific antibody. On the other hand, the S165N mutant
showed reduced expression level of phospho-α-tubulin compared to the wildtype or the
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Figure 3.4: Western blot of whole cell lysates prepared from MCF-10A cells expressing the empty
vector (VC), wildtype (WT) or phospho-resistant mutant (S165N) of α6-tubulins. Cells were
treated with DAG-lactone (10µM) or DMSO (0.05% v/v). Following an overnight IP with 250300ng/µl lysates with myc-antibody (1:200), phospho-α-tubulin bands of immunoprecipitated
pellets were detected with the TP4131 antibody (1:4000) (raised against a peptide containing the
phosphorylated Serine165 residue of α6-tubulin, ECM Biosciences) and anti-α-tubulin antibody
(1:2000, Epitomics) (Methods) to confirm the position of endogenous tubulin. Bands near 50 kDa
with phospho-α-tubulin antibody (TP4131) signified the specificity of the antibody towards the
phosphorylated state of α-tubulin in MCF-10A cells maintained under different conditions of
phosphorylation.

vector control thereby confirming its resistance to phosphorylation even after treatment with
DAG-lactone. This reaffirms Ser165 to be the only major site in α6-tubulin that is
phosphorylated by DAG-stimulated PKC isoforms. Also, it establishes the specificity of the
antibody TP4131 towards the phosphorylated S165 residue. However, this antibody was not
very efficient in terms of analyzing further details of the incorporation of mutants in existing
MT polymers and therefore was not used for further experiments.
To address the distribution pattern of myc-tagged α6-tubulin between intact MTs by a
classical approach, whole cell lysates expressing wild-type or the mutants of α6-tubulin were
fractionated into intact MTs (insoluble pellet, dark grey bars, Figure 3.5B) and
unincorporated α/β-tubulin dimers (soluble fraction, light grey bars, Figure 3.5B) for assay by
Western blot with either anti-myc or anti-α-tubulin (see Methods).
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Figure 3.5: Phosphorylation of α6-tubulin increases its partitioning into MTs (insoluble fraction).
(A) Western blot showing the level of myc-tagged WT-α6-tubulin from MCF-10A cells treated
with DAG-lactone (WT + DAG) or DMSO (WT), or α6-tubulin mutants (S165D/S165N) isolated
in insoluble (25 µg protein per lane) and soluble fractions (100 µg protein per lane). Each sample
represented 25% of the fraction volume. Myc-tagged α6-tubulin proteins were detected with antimyc (rabbit monoclonal myc-antibody, Cell Signaling) and the total level of α-tubulin present in
each set of samples was detected by Western blot with anti-α-tubulin (DM1A, Sigma), as
described in ‘Methods’. β-actin levels served as the loading control for the soluble fraction. The
results are representative of three independent experiments that gave similar results. (B) From
Western blots, the distribution of myc-α6-tubulin signals between the insoluble (dark grey bars)
and soluble (light grey bars) fractions were quantitated by Image J. The values are represented as
a fractional distribution of the total myc signal calculated for insoluble and soluble preparations.
The results are the average + s.d. of three independent experiments (n = 3). Statistical significance
was evaluated by the Student’s t-test: (*, p<0.05; **, p<0.005).

While the total pool of native α-tubulin was distributed between the insoluble and soluble	
  
fractions in a constant ratio of 55:45 (insoluble:soluble) for all samples (not shown), the
distribution of myc-tagged α6-tubulin was found to vary with its phosphorylation state. The
results (see Figure 3.5A) showed that myc-tagged WT-α6-tubulin expression along with
DAG-lactone treatment or expression of myc-tagged S165D-α6-tubulin mutant resulted in a
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far greater extent of incorporation when compared with the WT-α6-tubulin in untreated cells
or expression of the S165N mutant. Hence, in control cells expressing myc-WT-α6-tubulin,
the insoluble fraction displayed 41% of the total myc signal (insoluble plus soluble), whereas
in cells expressing myc-WT-α6-tubulin and treated with DAG-lactone, or simply expressing
the myc-tagged S165D mutant, the insoluble fraction incorporated 58% and 60% of the total
myc signal, respectively (see Figure 3.5B). In view of the fact that the S165D mutant is
refractory to dephosphorylation, the close similarity of the two values is interesting as it
suggests that phosphatase activity is only weakly reversing the DAG-stimulated
phosphorylation of WT-α6-tubulin. In stark contrast, expression of the myc-tagged S165N
mutant displayed only 31% of the myc signal in the insoluble fraction, which represented an
almost 30% lower incorporation than the S165D mutant, and a decrease by 10% when
compared to the myc-tagged WT-α6-tubulin in control cells. Therefore, phosphorylation (or
pseudo-phosphorylation) of α-tubulin is sufficient to promote its preferential incorporation
into growing MTs. 	
  

3.1.2.5: Phosphorylation of α-tubulin promotes higher incorporation and stability of
MTs
The pattern of MT incorporation of phosphorylated α-tubulin was also visualized by
immunofluorescence of intact cells (see Figure 3.6). In these experiments, only the
incorporated

myc-tagged

α-tubulin

was

detected

since

any

unincorporated

monomer/heterodimeric species had been removed from fixed cells by multiple wash steps.
DAG-lactone treatment induced the incorporation of myc-WT-α6-tubulin (green signals,
Figure 3.6A) to an extent that was comparable to that of the endogenous α-tubulin (red
signal, Figure 3.6A). Under these conditions, myc-WT-α6-tubulin was evenly distributed
along the entire length (from base to tip) of MTs growing into membrane protrusions (see
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Figure 3.6: Immunofluorescence of MCF-10A cells expressing myc-tagged wildtype or mutant α6tubulin. (A) Incorporation of myc-tagged WT α6-tubulin was compared in cells pretreated for 1 h
with 10 µM DAG-lactone or DMSO (0.05% v/v), and in cells transfected with S165D or S165N
α6-tubulin mutants. Following fixation cells were stained with myc antibody to delineate each
myc-tagged α6-tubulin (mutant or WT) (green) and counter-stained with α-tubulin antibody to
display total α-tubulin (red). Images acquired at 100x objective. Bar, 10 µm. A small area (red
box) is enlarged in the adjacent image. (B) Co-localization of myc-tagged tubulin (green) with
endogenous MTs (red) in immunochemically stained MCF-10A cells were analyzed by Pearson’s
index (rp) (‘Methods’). Results are the average of signal intensities from 20-24 cells for each
condition from three independent experiments. (*, p<0.0001). (C) Quantitation of the number of
myc-tagged signals (green) at the cell periphery was performed with Image J in cells either
transfected with the indicated mutant α6-tubulin, or WT and treated with or without DAG-lactone
(10 µM) (dark grey bars). Each value was normalized to the WT (minus DAG-lactone) condition.
To assess MT stability under these conditions, a similar measurement of myc signals was
performed with cells treated with DMSO or 300 nM nocodazole for 1 h (light grey bars), followed
by fixation and staining, as described in (A). Results are the average of signal intensities from 1824 cells for each condition from three independent experiments. (*, p<0.0001).

Figure 3.6A) as shown by the yellow signals and the alternating red-green coloration of
highly elongated MTs (inset).
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A. CONTROL

B. DAG-lactone

S165D

S165N

Figure 3.7: Immunofluorescence of MCF-10A cells expressing pseudo-phosphorylated S165D or
phosphorylation-resistant-S165N mutants of α6-tubulin and treated with DAG-lactone (10 µM).
Representative merged images of cells were stained with myc-tagged α-tubulin (green) and
endogenous-MTs (red) are shown. Results showed that serine 165 residue on α-tubulin is the
major site of phosphorylation by PKC, further treatment of S165N-expressing cells with DAGlactone did not improve its incorporation along endogenous MTs. Images were taken by 100x
objective. Scale bar is 10 µm.

In contrast, control-treated cells displayed very weak incorporation of myc-WT-α6-tubulin,
consistent with the slight myc-WT signal incorporated into the insoluble fraction, as found by
Western blot (see Figure 3.5). The incorporation of each myc-α6-tubulin mutant into MTs
was addressed in a similar fashion. As was found for DAG-lactone-treated cells, myc signals
(green) were observed to extend entirely along the MTs (red) for myc-S165D-α6-tubulin. In
contrast, only slight incorporation of the phosphorylation-resistant myc-S165N mutant was
observed; for this mutant, the myc signal (green) was primarily localized to MT structures in
the cell interior. Nonetheless, MTs continued to elongate by incorporating the endogenous αtubulin protein (red signals). Further treatment of these cells with DAG-lactone did not
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improve the incorporation of the myc-S165N mutant into MTs (see Figure 3.7). These results
implied that when phosphorylation at S165 was blocked, there was very limited incorporation
of this α6-tubulin mutant into growing MTs.
The images of cells obtained by immunofluorescence (were analyzed by estimating Pearson’s
correlation coefficient (rp) (Bolte and Cordelieres, 2006) that describes the degree of colocalization of myc signals and MTs (see Figure 3.6B). In fluorescence microscopy, colocalization is defined as the spatial overlap of two or more different types of molecules, each
having different wavelengths of emission, and occurring within a three-dimensional volume.
Co-localization does not refer to the composite image which is produced by an overlap of
signals from two or more fluorophores having similar emission spectra. Rather, it relies on
the co-occurrence of two or more possibly unrelated fluorophores with different emission
spectra sharing the same pixel and finding a statistical relation between them. For this
purpose, the fluorochromes with red and green emission wavelengths were chosen such that
the two signals do not ‘bleed through’ or ‘crosstalk’ with each other and generate a composite
image yet having a degree of separation between their respective emission wavelengths.
Pearson’s correlation coefficient (PCC or rp) is one of the standard methods of pattern
recognition and is commonly used for matching one image with the other and characterizes
the degree of overlap between each other (Manders et al., 1993). PCC measures pixel-bypixel covariance in the signal levels of two images without regards to the average intensity of
the individual signals or the signal offset (background or noise).
In control and DAG-lactone-treated cells, values of rp = 0.7 and 0.85, respectively, implied
that DAG-lactone induced 21% higher co-localization of myc-tagged WT-α6-tubulin (green)
and endogenous MTs (red). This finding is in good agreement with the 17% higher
incorporation of the WT protein in DAG-lactone treated cells found in isolated MTs (Figure
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3.5). Similarly, S165D-α6-tubulin-expressing cells gave rp = 0.81, while cells expressing the
S165N mutant gave rp = 0.59. Thus, the pseudo-phosphorylated mutant produced a 37%
higher co-localization of the two signals than the phosphorylation-resistant mutant (see
Figure 3.6C). The rp value for S165N mutant was found to be approximately 16% less than
that for WT-α6-tubulin in control cells, indicating that the degree of incorporation and
distribution of phosphorylation-resistant mutant along MT polymers was less than WT-α6tubulin in the (untreated) basal condition. The decreased incorporation of S165N-α6-tubulin
in MT polymers corresponded well with the reduced level of insoluble fraction in the
fractionation assay (see Figure 3.5).
Next we investigated whether site-specific phosphorylation confers any stability to the MTs
that resulted in ‘curved or whip-like structures’ near membrane peripheries as observed
repeatedly in live cell imaging or immunofluorescence. Cells expressing either myc-tagged
WT and treated with DAG-lactone (or DMSO) or the mutants (S165D and S165N) of αtubulin were used for this analysis. The average myc-signals (green, Figure 3.6A) retained
along MTs near cell peripheries was quantified by ImageJ (Methods). Results showed that
the average signals of myc-tagged α-tubulin incorporated along MTs was considerably higher
due to either DAG-lactone treatment of MCF-10A cells or by expression of the S165D
mutant (Figure 3.6C, dark grey bars).
To assess stability under these conditions of α-tubulin phosphorylation, cells (expressing
myc-tagged-WT or mutant α-tubulin) were treated with 300 nM of the MT depolymerizing
drug nocodazole (NOC) for 1 h (along with DAG-lactone for WT only). The average
intensity of myc-signals along MTs near the cell periphery was quantified to obtain an index
of MT-stability – the higher the retention of myc-tagged α-tubulin signals in MTs, the greater
the stability. The cells exhibited a differential sensitivity to this destabilizing drug whereby
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both DAG-lactone treatment and expression of the S165D mutant showed much higher
average intensities compared to their respective negative controls. This suggests that by
getting incorporated to a greater extent in the existing MT polymers, α-tubulin
phosphorylation enhances the overall relative stability of MTs (Figure 3.6C, light grey bars).

3.1.2.6: DAG-lactone increases the number of EB1-EGFP-bound MT plus-ends in
MCF-10A cells
Due to the dense population of MTs in cell, it is difficult to study and quantitate their
dynamic events especially near the cell center (centrosome). In 2003, Piehl et al. devised a
new method to quantify microtubule nucleation throughout the cell cycle by using green
fluorescent protein (GFP) to tag EB1, a protein that binds to the growing (+) ends of
microtubules. This method reliably allows quantitation of the microtubule behavior at the
centrosome or near the cell periphery (Salaycik et al., 2005). EB1-EGFP provides an
additional tool to EGFP-tagged α-tubulin which is used to track the entire length of MTs to
study their dynamicity in live-cells (Cassimeris et al., 2013). Like other members of the
microtubule tip binding protein family (+TIPS), EB1 plays an active role in the MT-mediated
cell migration, division and morphogenesis (Su and Qi, 2001), (Vaughan, 2005), (Morrison,
2007).
In order to determine whether DAG-lactone affected the actual number of MTs, cells were
transfected with the plus-end binding protein EB1-EGFP. This protein can be tracked by
fluorescence microscopy due to the comet-like fluorescence track of EB1-EGFP proteins
bound at growing MT plus-ends (Matov et al., 2010). Cells were fixed at selected time points
following DAG-lactone treatment and viewed under the fluorescence microscope. The
fluorescence images in Figure 3.8A depict EB1-EGFP signals polarized towards flat
membrane protrusions in control and DAG-lactone-treated cells.
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Figure 3.8: Fluorescent live cell imaging of MT growing ends with EB1-EGFP in MCF-10A cells.
(A) Images show the arrival of EB1-EGFP comets near the cell periphery following a 1 h
treatment with DAG-lactone (10µM) or DMSO (0.05% v/v). (B) Quantitative analysis of EB1EGFP signals per 100 µm2 area near the cell periphery following treatment with DAG-lactone (n =
1800 signals, 14 cells) or DMSO (n = 1112 signals, 16 cells). Bar, 10 µm. The results are
represented as the average number of EB1 comets from three independent experiments (*,
p<0.0001). (C) After initially treating cells with (6.6 µM) NOC followed by washout of the drug
(see ‘Methods’), the appearance of EB1-EGFP comets bound to nascent MTs in cells was detected
after 0.5-5 min incubation with DAG-lactone (10 µM) or DMSO (0.05% v/v). One representative
image from 0.5 min incubation with DAG-lactone or DMSO after NOC wash out has been shown.
(D) In cells treated with 10 µM DAG-lactone (dark grey bars) or DMSO (light grey bars), the
number of nascent MTs in 18-55 cells treated with DAG-lactone for the indicated time intervals
was quantified with ImageJ and averaged. (*, p<0.0001; **, p<0.05).

When EB1-EGFP-expressing cells were analyzed for MT comets approaching the cell
periphery, the number of EB1-EGFP-bound plus-ends detected in the cell periphery
approximately doubled in response to DAG-lactone (Figure 3.8B). This finding implied that
DAG-sensitive PKC activity maintains a significantly higher number of growing MTs that, as
a result of the prolonged growth phase, continue to elongate all the way to the periphery.
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The number of MTs produced by DAG-lactone treatment was assessed with 6.6 µM
nocodazole (NOC) to eliminate all pre-existing MTs, followed by wash-out of the drug and
DAG-lactone treatment. As early as 0.5 min following DAG-lactone addition, the appearance
of EB1-EGFP signals could be detected and signified the presence of nascent MTs (Figure
3.8C). At the 0.5 min time point, DAG-lactone treatment significantly increased the number
of EB1-EGFP signals relative to control cells that rapidly increased for up to 5 min (Figure
3.8D). The statistically significant higher numbers of EB1-EGFP signals (Figure 3.8D) was
evident throughout this 5 min growth period. This observation was consistent with increased
MT stability conferred by DAG-lactone (Figure 3.6C) that becomes apparent even during this
earliest phase of the MT lifespan.

3.1.2.7: DAG-lactone results in delocalization of gamma-tubulin in MCF-10A cells
Microtubules emanate from a small organelle in centrosome known as the microtubuleorganizing center (MTOC). Microtubule nucleation in MTOC region in mammalian cells
involves several proteins which constitute the gamma-tubulin-ring complex (gamma-TuRC).
Unlike alpha and beta tubulin that constitute the MT filaments, gamma tubulin is a low
abundance protein which constitutes the gamma-TuRC in centrosome. It is involved in MT
nucleation and capping of minus ends of MTs.
Centrosome abnormalities are common hallmarks of breast cancer and are known to cause
aneuploidy, mitotic defects, and aberrant cellular motility (Cho et al., 2010). Breast cancer
has been known to be associated with centrosome amplification and aberrant microtubule
nucleation beyond mitosis. Studies across a panel of breast cancer cell lines with varying
degrees of tumorigenicity showed an aberrantly increased level of gamma-tubulin in the
cytoplasmic pool in highly aggressive tumor cells. Moreover, once incorporated into
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A. DMSO

B. DAG-lactone

GAMMA-TUBULIN

GAMMA-TUBULIN
+ NUCLEAR STAIN

Figure 3.9: Immunofluorescence of MCF-10A cells stained with gamma-tubulin (red) and nuclear
Hoechst stain (blue). Cells treated with DAG-lactone (10µM) or DMSO (0.05% v/v) were fixed at
-20 oC in methanol for 5 min, washed twice in PHEM buffer before staining with gamma-tubulin
antibody. DAG-lactone-treated cells (column B) show delocalization of gamma-tubulin polymers
(red punctate signals indicated with yellow arrows) from the cell center into the cytoplasm and
near the membrane periphery of leading edges as compared to the control (column A). Results are
representative of three independent experiments. Images were taken by 63x objective. Scale bar is
10 µm.

cytoplasmic MTs, gamma-tubulin conferred resistance to colchicine-mediated catastrophe
and promoted aberrant MT structures commonly seen in breast tumors (Cho et al., 2010).
Earlier we had shown the influence of DAG-lactone in stimulating nascent MTs from their
nucleation sites in centrosome, which are maintained throughout MT growth to the
membrane periphery. We next addressed the question of whether the increase in the number
of nascent MTs arises due to an amplification of gamma-tubulin or nucleation sites
stimulated by DAG-lactone treatment.
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Cells were fixed in methanol at -20oC for 5 min following DAG-lactone treatment and
stained for gamma-tubulin. Our results showed that upon DAG-lactone treatment there was a
delocalization of gamma-tubulin in MCF-10A cells compared to the control or parental cells
that largely showed a centrosomal location of the gamma-tubulin protein (Figure 3.9A).
Apparently, DAG-lactone treatment promoted translocation of gamma-tubulin from the
centrosomal region into lamellipodia and the membrane periphery, as seen in Figure 3.9B.
However, there were no changes to the number of nucleation sites or the expression level of
gamma-tubulin protein in these cells following DAG-treatment.
Centrosome location of gamma-tubulin is commonly seen in less-aggressive non-motile cells.
Enhanced migration and metastasis is correlated with translocation of gamma-tubulin
polymers into the cytoplasm. Thus, DAG-lactone-mediated PKC activation which conferred
motility in non-aggressive MCF-10A cells also resulted in delocalization of gamma-tubulin
polymers.

3.1.2.8: Pseudo-phosphorylated α6-tubulin promotes Rac1-driven cell movement
The small GTPases are known to participate in mechanisms that drive cell movement (Ridley
et al., 1992; Waterman-Storer et al., 1999; Banyard et al., 2000; Hanna and El-Sibai, 2013).
Since an earlier report from this laboratory implicated Rac1 in PKC-driven motility of MCF10A cells, the activation of Rac1 to its GTP-bound state was analyzed in cells treated with
DAG-lactone. In Figure 3.10A, cells treated with or without DAG-lactone were probed with
an antibody that recognizes the active form of Rac1 (New East Biosciences). The results
indicated that activated Rac1 signals were increased overall following DAG-lactone
treatment, and could be detected in membrane ruffles. To analyze the effect of α-tubulin
phosphorylation on the activation state of each of the small GTPases (Rac1, Cdc42, and
RhoA), a pull-down assay was performed.
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Figure 3.10: Rac1 undergoes activation in cells expressing S165D-α6-tubulin. (A) Evidence of
activated Rac1 in membrane ruffles of MCF-10A cells. Immunofluorescence of cells treated either
with DMSO (0.05% v/v, control) or DAG-lactone (10 µM, 1h) was performed followed by
fixation with 4% PFA and addition of anti-active Rac1 antibody (1:100). With DAG-lactone
treatment, Rac1 localized to membrane ruffles (arrows). Scale bar, 10 µm. (B) Western blot
analysis of the level of GTP-bound Rac1, Cdc42, or RhoA in response to S165D or S165N α6tubulin mutants, or the vector control (VC). The immunoblot shows the results of pull-down
assays with whole cell lysates (600 µg per sample), as described in ‘Methods’. The results are
representative of three independent experiments. (C) Motility of MCF-10A transfectants
expressing wildtype PKCα, S165D-α6-tubulin, or the empty vector (VC) was measured with or
without the Rac1 inhibitor NSC23766 (75 µM) (in water). Measurements show the increase in
area occupied by the cells in triplicate samples after 8 h of treatment (‘Methods’). (*, p<0.0001)
The results are representative of three independent experiments.

MCF-10A cells expressing the pseudo-phosphorylated mutant of α6-tubulin (S165D) or
phosphorylation-resistant mutant (S165N) were prepared into lysates. Each lysate was
incubated with either PAK-PBD-agarose to pull-down activated Rac1 and Cdc42, or
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Rhotekin-agarose to pull-down RhoA.

Each reagent bound its target only if the G-protein

had undergone activation to the GTP-bound (activated) state, whereupon the extent of
activation was detected by western blot with a G-protein-specific antibody. As shown in
Figure 3.10B, cells expressing the S165D mutant resulted in stronger signals for GTP-Rac1
than did cells expressing the S165N mutant or vector control. In contrast, GTP-Cdc42 and
GTP-RhoA signals were not affected by expression of either α6-tubulin mutant. Thus, Rac1
undergoes activation by treatment with DAG-lactone or expression of the S165D mutant.
The significance of GTP-Rac1 to the motility phenotype actuated by the S165D mutant was
analyzed by use of a Rac1 inhibitor (NSC23766). This cell-permeable molecule prevents
Rac1 activation by inhibiting binding of Rac1-specific guanine nucleotide exchange factors
(GEFs) without affecting activation of either Cdc42 or RhoA (Nassar et al., 2006). As shown
in Figure 3.10C, cells transfected with either WT-PKCα or S165D-α6-tubulin, exhibited
motility that was strongly elevated (by 4-fold), as previously reported [Abeyweera et al.,
2009]. In each condition, motility could be inhibited by 75% by treatment with NSC23766.
Taken together, our findings describe a model in which PKC-mediated phosphorylation of αtubulin promotes numerous, stably elongating MTs that by an unknown mechanism leads to
the formation of GTP-Rac1, consequently eliciting downstream events that promote cell
movement.

3.1.3: Discussion
The research presented here explored the mechanistic pathway of cell movement driven by
PKC-mediated phosphorylation of α-tubulin. It was shown that phosphorylation of α-tubulin
at Ser-165 favors the incorporation of α-tubulin into MTs that in turn prolongs the duration of
MT growth. This outcome results in more numerous and relatively longer MTs that extend
into membrane protrusions of the cell cortex, consequently eliciting downstream events (such
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as Rac1 activation) that produce cell movement. The activation of Rac1 had previously been
attributed to PKC activity in MCF-10A cells (Sun and Rotenberg 1999; Abeyweera et al.
2009).
How phosphorylation of Ser-165 in α-tubulin promotes MT growth and stabilization may lie
in the strategic location of this site in the context of a growing polymer of α/β-heterodimers.
The physical site of Ser-165 lays at the surface of the α-tubulin subunit of an incoming
heterodimer that dock with the plus-end β-tubulin subunit (Abeyweera et al., 2009). Due to
the preferential incorporation of pseudo-phosphorylated S165D-α-tubulin into growing MTs
(Figure 3.5, Figure 3.6), we propose that DAG-lactone stimulates PKC to phosphorylate αtubulin as a monomer or as part of an α/β-tubulin heterodimer. The resulting negatively
charged phosphate group at Ser-165 may strengthen binding and electrostatic interactions
between successively added α/β-heterodimers, thereby supporting MT stabilization and
persistent growth. However, the precise mechanism by which phosphorylation (or pseudophosphorylation) promotes this phenomenon is unknown at this time. Further study of MT
polymerization in the presence of mutant α-tubulin will require kinetic analysis in vitro with
highly pure components.
The effect of phosphorylation on parameters that sustain MT growth was observed with
either a membrane-permeable PKC activator (DAG-lactone) or by expression of α6-tubulin
bearing a pseudo-phosphorylated mutation at Ser-165. The increased dynamicity produced by
α-tubulin phosphorylation or pseudo-phosphorylation arose from an increased rate and
duration of MT growth coupled with decreased pause duration and frequency of catastrophe.
This impact by PKC on MT dynamic parameters may be a general phenomenon since similar
observations of PKC-associated effects on MT dynamics were reported during outgrowth of
axonal cells treated with a phorbol ester PKC activator, PDBu (Kabir et al., 2001). However,
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the precise targets sites through which PDBu impacts MTs was not investigated in that study.
In addition to exploring the impact on MT dynamics by DAG-lactone or phosphorylation
site-specific mutants of α-tubulin, the present study showed that these conditions also
produced an increase in the number (by 2-fold) of EB1-EGFP-bound growing MTs arriving
at the cell margin (Figure 3.8A, Figure 3.8B) and enhanced MT stability (Figure 3.6C, Figure
3.8C and Figure 3.8D). Although not directly addressed by this work, these changes are
likely to contribute to an increased protrusive force expressed at the leading edge of the
moving cell.
A comparison of MT dynamic parameters operating in non-transformed, non-motile MCF10A cells (Table 3.1) and triple negative, metastatic MDA-MBA-231 cells (Table 3.2)
revealed complementary profiles.

Among the parameters analyzed, the duration of the

growth phase was most dramatically influenced by the state of Ser-165 phosphorylation in αtubulin and therefore provided a basis for comparing the two cell lines (Figure 3.3). In terms
of this parameter, the results clearly portrayed the differences in a non-motile cell (MCF10A) and an aggressively moving cell (MDA-MB-231) whose intrinsic motility is being
driven by PKC-mediated phosphorylation of α-tubulin. In metastatic cells, blockade of Ser165 phosphorylation by expression of the S165N mutant corrected the intrinsically high rate
and duration of MT growth to values found for non-motile MCF-10A cells, and correlated
with the previously reported inhibition of motility of MDA-MB-231 cells by this mutant
(Abeyweera et al., 2009). The impact of the S165N mutant on MT dynamics is tantamount to
complete PKC inhibition and strengthens the mechanistic basis for including a potent PKC
inhibitor for chemotherapeutic control of breast cancer metastasis.
The growing MT is polarized toward membrane protrusions such as lamellipodia (Komarova,
et al., 2009) through cortical membrane interactions afforded by the presence of a binding
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protein such as EB1 or CLIP-170 at the MT plus-end. The capture of MTs at the membrane,
especially at the leading edge, is thought to be facilitated by an interaction of the plus-end
binding protein (e.g. EB1 or CLIP-170) with a membrane-associated small GTPase (Rac1 or
Cdc42) (Fukata, Watanabe et al. 2002; Wittmann 2003) and (Waterman-Storer et al., 1999),
leading to the formation of a complex with IQGAP (Fukata et al., 2002; Noritake et al.,
2005). The activated Rac1-IQGAP complex apparently elicits a series of events in the actin
cytoskeleton and membrane (Wittmann 2003), leading to polarized cell movement. This
segment of the signaling pathway has been shown be activated by PKC (Shober et al., 2012).
The next section in this chapter will address the possible interaction of IQGAP, Rac1 with αtubulin.
At the leading edge, MTs encounters GEFs and GAPs that enable Rac1 cycling between
GTP-bound and GDP-bound forms (Etienne-Manneville, 2013). In an earlier report from this
laboratory, we found that a dominant negative form of Rac1 inhibited PKC-mediated
motility, whereas dominant negative forms for Cdc42 or RhoA had no effect (Sun and
Rotenberg, 1999). Our current study showed that these cells express active Rac1, the level of
which is highly elevated upon expressing the pseudo-phosphorylated-α-tubulin compared to
its phosphorylation-resistant form (Figure 3.10B). Furthermore, Rac1 inhibition by
NSC23766 (which inhibits GEF-mediated GDP–GTP exchange) was strongly inhibitory to
motility promoted by MTs expressing S165D-α6-tubulin (Figure 3.10C) (X. Chen, Ph.D.
Thesis, 2010).
In an earlier report, it had been shown that the growth phase of MT dynamic instability
promotes lamellipodial protrusions by locally activating Rac1 near leading edges of
fibroblasts (Waterman-Storer et al., 1999). Our findings implied that a constant supply of
steadily growing MTs as the result of having incorporated S165D-α-tubulin, leads to local
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activation of Rac1 (GTP-bound) near the periphery of cell leading edges which consequently
drives cell movement. In contrast, the S165N mutants or control MTs fail to reach the
membrane periphery and activate Rac1. We propose that phosphorylation of α6-tubulin
results in dynamically active MTs and an increased number of MT ends, that upon contact
with Rac1 activates it near leading edges of cell membranes. This phenomenon therefore
increases the probability of productive MT capture by Rac1, and consequently triggers Rac1mediated downstream signaling events and cell movement. Although the precise molecular
mechanism by which growing MTs lead to Rac1 activation is not known at this time, we
speculate that elongating MTs interact directly or indirectly via plus-end protein(s) with
GEFs/GAPs, thereby elevating local GTP-Rac1 levels. The significance of Rac1 cycling to
cell movement, particularly in cancer cells, provides an avenue for further study (Wertheimer
et al., 2012).
The α-tubulin mutants used in these studies were constructed with the α6-tubulin isotype
which was previously identified from MCF-10A cells in its phosphorylated form (Abeyweera
et al., 2009). However, there are eight known isotypes of human α-tubulin, all having a Ser
residue at a PKC consensus site analogous to Ser-165 in α6-tubulin. Therefore, all of the
native α-tubulin isotypes can be regarded as potential substrates of PKC. While it is presently
unknown which isotypes, other than α6-tubulin, are expressed in MCF-10A cells, it is not
likely that they would have interfered with the α6-tubulin mutants being tested. An important
reason is that these non-motile cells produce undetectable levels of endogenous phospho-αtubulin due to low PKC activity (Abeyweera et al., 2009).

Against this negligible

background of PKC activity, the S165D mutant produced the same impact on MT dynamics
as the endogenous phospho-α-tubulin that was generated by DAG-lactone-stimulated PKC
activity
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Previous studies reported that mutations occurring in α- or β-tubulin consequently impact MT
stability and cell motility (Hari et al., 2003; Ganguly et al., 2012). Such anomalies have been
implicated in different disease states (Tischfield et al., 2010) and drug resistance (VerdierPinard et al., 2003). These mutations affect the binding sites of MAP proteins and GTP
molecules, lateral contacts between adjacent microfilaments, and longitudinal interactions
within and between heterodimers. Our findings suggest that mutation of Ser-165 in α-tubulin
to a residue that could serve as a phosphate mimic (such as Asp or Glu) may provide an
important predictive marker for metastatic breast cancer.
Based on our observations, we propose that phosphorylation of α6-tubulin by DAG-sensitive
PKC isoforms results in an increased number of stable elongating MTs reaching membrane
peripheries. This facilitates an interaction and enhanced activation of Rac1, thereby
increasing the local pool of MTs by MT-Rac1 capture at the leading edge. This high density
of MTs generates a driving force that triggers cell movement. The precise means by which
the higher number of growing MTs activates Rac1 and other unidentified consequences
provide an avenue for further study.

3.2: Interaction of phospho-α-tubulin with IQGAP and Rac1

3.2.1: Introduction
The IQ-domain GTPase-activating proteins (IQGAP) are a family of multi-domain proteins
that play diverse roles in regulating cell-cell adhesion, cell migration, cell division, and
extracellular signals (Johnson et al., 2009). While IQGAP1 is ubiquitously expressed,
IQGAP2 is expressed in the liver and intestinal tract, and IQGAP3 is expressed in the brain
and testis. IQGAP has a wide distribution in cells and can be found near perinuclear regions,
in the cytoplasm, in cell-cell contact regions, and in lamellipodia.
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IQGAP1 is ~190 kDa multi-domain protein that consists of four centrally located calmodulin
binding IQ motifs and a C-terminal Ras-GAP-related domain (GRD). Unlike the
conventional GTPase-activating proteins (GAPs), IQGAP does not express detectable
GTPase activity. Instead, IQGAP1 stabilizes the active form of small GTPases, i.e. the GTPbound form. Of the known small GTPases, Rac1 and Cdc42 are the best characterized
IQGAP1 downstream effector proteins (Owen et al., 2008). Consistent with these findings, an
overexpression of IQGAP1 in human breast cells has been found to increase the GTP-bound
form of Cdc42 thereby stimulating the formation of filopodia, while a knockdown of
IQGAP1 with RNAi prevents these effects (Owen et al., 2008). In addition, IQGAP1 helps to
localize Cdc42 in the cell membrane, and binds to active Rac1 and Cdc42 to partially
promote cell motility. Other small GTPases known to interact with IQGAP1 are Rac2, Rap1,
RhoC and Arp6 (ADP-ribosylation factor), the functions which remain largely unknown
(White et al., 2012).
Besides interacting with Rac1/Cdc42 complex, IQGAP1 regulates cytoskeletal structure by
directly interacting with actin to promote polymerization and cross-linking of actin filaments.
It also regulates MT dynamics by interacting with CLIP170 in a process controlled by
Cdc42/Rac1 complex. The MT plus end binding protein CLIP170 has been known as a
rescue factor for shrinking MTs near cell leading edges. The IQGAP1/CLIP170 complex
promotes transient capture of MTs at the cortical regions of cell-leading edges and thereby
increases the concentration of MTs. This MT capture mechanism enables the formation of
actin-based structures and membrane ruffles, which are prerequisites for cell migration
(Owen et al., 2008; Fukata et al., 2002).
The invasive potential of IQGAP1 in tumor cells has also been investigated. Many of the
binding partners of IQGAP1 contribute to malignant transformation and tumor progression.
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Studies indicate that the IQGAP1 gene is amplified in gastric cancer cell lines, lung and
colon cancers. An over-expression of IQGAP1 has resulted in enhanced proliferation and
formation of invasive tumors of immortalized MCF-7 cells. The highly metastatic breast
epithelial cells like MDA-MB-231 express very high levels of IQGAP1, suggesting a positive
relationship between IQGAP1 expression and metastasis (Owen et al., 2008; Johnson et al.,
2009).
Earlier we had shown that phospho-α-tubulin result in enhanced cell migration by increasing
MT dynamicity and growth rates, prolonging growth phases and recruiting more of active
Rac1 complex near membrane peripheries. There can be a possible involvement of IQGAP1
in this course of events that facilitates cell migration. The current study therefore explores the
effect of phosphorylated (or pseudo-phosphorylated) α6-tubulin on the co-localization of
IQGAP1 and Rac1 in MCF-10A cells.

3.2.2: Results

3.2.2.1: DAG-lactone stimulates IQGAP1 localization in cell-leading edges and promotes
membrane ruffling
The question addressed by these studies was whether phospho-α-tubulin influences the
accumulation and distribution of the active Rac1/IQGAP complex at the membrane periphery
thereby facilitating enhanced migration of cells. We addressed this issue by conducting
immunocytochemistry experiments with cells in which α-tubulin was phosphorylated, and
probing for either Rac1 or IQGAP signals.
Our initial results with fixed MCF-10A cells showed that upon DAG-lactone treatment, there
was an overall increase of active Rac1 signals both near perinuclear cytoplasmic regions and
the cell periphery compared to the untreated or control-treated cells. By use of an antibody
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Figure 3.11: Immunofluorescence of MCF-10A cells probed with activated Rac antibody. Cells
were fixed with 4% PFA, probed with activated Rac1 mouse antibody (1:100) (Red), and α-tubulin
rabbit antibody (1:250) (green) treated either with (A) DMSO (0.05% v/v, control) or (B) DAGlactone (10 µM, 1h). The enclosed boxes in panel B show intense Rac1 signals (yellow signals due
to co-localization) in membrane ruffles upon DAG-lactone treatment. Images were acquired at
100x oil objective.

that binds specifically to activate Rac1, we observed that some cells exhibited activated Rac1
signals near membrane ruffles as shown in Figure 3.11.). As seen in the figure, DAG-lactone
treatment resulted in enhanced Rac1 signals compared to the control cells. However, with this
technique we did not find any significant differences of Rac1 distribution in cells expressing
S165D or S165N mutants of α-tubulin (data not shown).
We next investigated the distribution pattern of IQGAP1 in MCF-10A cells. The non-motile
MCF-10A epithelial cells express low levels of IQGAP (Jadeski et al., 2008). Usually,
IQGAP was found to localize near cell-cell junctions, perinuclear regions and cytoplasm of
MCF-10A cells (Figure 3.12A) unlike its complete leading edge distribution in highly
metastatic cells (Owen et al. 2008). Upon treatment with DAG for an hour, and subsequent
staining, IQGAP was found to localize strongly near actin-rich membrane ruffles at the
periphery of migrating cells quite similar to the distribution pattern as observed in highly
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Figure 3.12: Immunofluorescence of MCF-10A cells probed with IQGAP1 (green), and actin stain
(red) treated either with (A) DMSO (0.05% v/v, control) or (B) DAG-lactone (10 µM, 1h). Cells
were fixed with 4% PFA, and the nucleus was stained by Hoechst stain. The migrating cell at the
leading edge of cell clusters shows IQGAP signals in actin-rich membrane ruffles upon DAGlactone treatment. Images were acquired at 63x oil objective. Scale bar is 10 µm.
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metastatic MDA-MB-231 cells (data in Section 3). Besides, there was a significant increase
in the signal intensity of IQGAP in cell-cell adhesion regions of non-migrating cells lying
near the center of cell clusters (Figure 3.12B).
The epithelial-derived cancer cells undergo an epithelial-mesenchymal transformation
(EMT) to gain a motile and invasive phenotype. The EM-transition is associated with the loss
of adherens junctions (cell-cell contacts), and disruption of apico-basal polarity thus
contributing to a transformed phenotype. Usually, IQGAP is found in cell-cell contacts in
epithelial cells, and it plays a significant role in regulating adherens-junction stability. Upon
over-expression or during tumorigenesis, IQGAP1 negatively regulates cell-cell adhesion by
getting dissociated from the adherens regions or by dissociating α-catenin from adherens
junctions through competitive binding with β-catenin. In cells undergoing EMT, IQGAP
forms a tripartite complex with N-cadherin and β-catenin that localizes near the invasive
fronts (Chao et al., 2010).
We found similar results with IQGAP/E-cadherin in DAG-lactone-induced motile MCF-10A
cells. There was an almost complete absence of E-cadherin signals near the leading edges of
migrating cells. The migratory cells were characterized by ruffling lamellipodia composed of
a localized dense meshwork of actin polymers and strong signals of IQGAP. On the contrary,
the control cells, lacking distinct membrane ruffles, mostly showed characteristic E-cadherin
signals near cell-cell contacts, and in the cytoplasm to a certain extent (Figure 3.13A, Figure
3.13B). Here, some cells also showed E-cadherin signals at cell edges (data not shown). In
summary, the migrating cells showed a distribution pattern of IQGAP1 that did not overlap
with E-cadherin signals. However, in non-migrating cells (control conditions), cells, IQGAP
and E-cadherin showed overlapping signals.
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Figure 3.13: Immunofluorescence of MCF-10A cells probed with IQGAP and E-cadherin. After
fixation with 4% PFA, cells were probed with IQGAP1 (green), and E-cadherin (red) and treated
either with (A) DMSO (0.05% v/v, control) or (B) DAG-lactone (10 µM, 1h). The control cells
(11A) lack distinct IQGAP signals but show intense E-cadherin signals at cell-cell junctions.
Following DAG-lactone treatment (B), cells exhibit stronger IQGAP signals and an almost
complete absence of E-cadherin near cell leading edges. These cells show stronger E-cadherin
signals at cell-cell junctions. Images were acquired at 63x oil objective. Scale bar is 10 µm.
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3.2.2.2: DAG overrides the effect of a Rac1 inhibitor on IQGAP1 distribution in MCF10A cells
Since IQGAP1 has been known to localize with active Rac1 near membrane ruffles and
participate in cell migration, we next studied its pattern of distribution with active Rac1
inhibited by NSC23766. This cell-permeable inhibitor prevents Rac1 activation by inhibiting
Rac1-specific guanine nucleotide exchange factors (GEFs). Besides, it was also important to
ascertain whether further DAG treatment overrides the Rac-inhibitor driven changes in cells.
Alongside this, the distribution pattern of E-cadherin was also studied in cells in the
aforementioned conditions.
To investigate the first question, cells were treated with Rac inhibitor (75 µM) for ~2 h before
fixing and probed for IQGAP and E-cadherin. With an inhibition of active Rac1, the level of
IQGAP1 was significantly reduced near membrane ruffles of cells and attained a distribution
pattern similar to the parental cells (Figure 3.14A). This inhibitory condition was
characterized by an increased signal intensity of IQGAP1 in the cytoplasmic compartment of
cells (Figure 3.14A). Further staining of actin filaments or MTs in these cells showed no
changes in their morphologies upon Rac inhibiton (data not shown).
To address the next question of whether DAG-lactone mediated PKC activation overrides
Rac-inhibitor effects, cells were initially treated with Rac-inhibitor and then incubated with
DAG-lactone for 1 h (10 µM) without removing the inhibitor from the medium. After
incubation, the cells were fixed and stained for both IQGAP and E-cadherin. As seen in
Figure 3.14B, DAG-lactone treatment resulted in the reappearance of IQGAP signals near
membrane ruffles of lamellipodial extensions formed by MTs. Whereas MTs constituted the
framework of lamellipodia, actins formed the docking sites for IQGAP near membrane
ruffles (Figure 3.15). This was in remarkable contrast to the condition when the cells were
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Figure 3.14: Immunofluorescence of MCF-10A cells treated with Rac inhibitor. Cells were probed
with IQGAP1 (green), and E-cadherin (red), and nucleus stain (blue) treated either with (A) Racinhibitor NSC23766 (75 µM in water, 2h) or (B) DAG-lactone (10 µM, 1h). While the Rac
inhibitor completely eliminated IQGAP signals from the membrane periphery of leading edges (A,
highlighted region), further DAG treatment with these cells, even in the presence of inhibitor,
reversed the inhibitory effect (B, marked zones). No significant changes were observed with Ecadherin as evident from the figure. All images were acquired at 63x objective. Scale bar is 10 µm.

treated with Rac-inhibitor alone. In the latter case, cells lacked polarity, membrane ruffles
and distinct localization of IQGAP in membranes.
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Figure 3.15: Immunofluorescence of MCF-10A cells probed with IQGAP1 antibody. Cells were
treated with DAG-lactone (10 µM, 1h) in presence of Rac inhibitor NSC23766 (75 µM in water,
2h) were fixed with 4% PFA and then probed with IQGAP1 (green) antibody, actin or MTs (red)
and Hoescht nuclear (blue) stain. Upon DAG-lactone treatment, IQGAP was strongly localized to
actin-rich membrane ruffles of cell-lamellipodia formed by MTs. MTs constitute the framework
of lamellipodia (membrane extrusions), actins form the docking sites for IQGAP near membrane
ruffles. Images were acquired at 63x objective. Scale bar is 10 µm.
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3.2.2.3: Effect of phospho-α-tubulin mutants on IQGAP1 distribution
Rac1 inhibitor prevents binding of Rac to GTP (Rac-GTP, active form), which, in its inactive
GDP-bound state, fails to interact with IQGAP1 near membrane peripheries and is thus
ineffective in promoting cell migration. Rac can interact with IQGAP1 only in its active,
GTP-bound form. As seen from the results described above, DAG-lactone mediated PKC
activation overrides the effect of the Rac inhibitor by allowing cells to attain a polarized
distribution pattern of IQGAP1. This can occur if either IQGAP1 is a direct PKC substrate
that upon phosphorylation acts in co-ordination with other accessory proteins near the
membrane periphery, or any other PKC substrates that in due course interact with IQGAP
and facilitate the orchestrated events of cell migration. It has been recently reported that
IQGAP1 is a PKCα substrate that is phosphorylated at Ser-1443 (White et al., 2012). Thus,
upon DAG-lactone treatment, IQGAP1 is phosphorylated by activated PKCα, and
subsequently localizes to actin rich membrane ruffles where it interacts with active Rac1.
There can also be a possible involvement of other PKC substrates, which interact with
IQGAP upon phosphorylation, and facilitate its transport from the cytoplasmic compartment
to the cell periphery.
We therefore investigated the role of PKC substrate α-tubulin in promoting IQGAP1
localization near membranes of cells. In the previous section, we demonstrated that S165D-αtubulin expressing cells exhibit higher growth rates, dynamicity of MTs and enhanced
migration compared to the S165N-mutants. Relative stability and elongated MTs conferred
by the S165D mutants might facilitate an increased localization of IQGAPs from cell
cytoplasm to the membrane periphery of cell leading edges, thereby enhancing cell motility.
Our results showed stronger IQGAP signals near cell-cell contacts of S165D-α-tubulin
expressing cells, whereas S165N-expressing cells displayed an overall weak signal (Figure
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A. IQGAP, S165D α-TUBULIN

B. IQGAP, S165N α-TUBULIN

Figure 3.16: Immunofluorescence of MCF-10A cells expressing α6-tubulin mutants and probed
with IQGAP1 antibody. Representative merged image from immunofluorescence of MCF-10A
cells expressing (A) S165D and (B) S165N-α-tubulin (red) probed with IQGAP1 (green) antibody
and nuclear stain (blue) has been shown. The S165N mutant showed an overall weak IQGAP
signals as compared to S165D. In both cases, the cells bordered a cell cluster. No distinct
compartmentalization of IQGAP was seen in either condition. Images were acquired at 63x
objective. Scale bar is 10 µm.

3.16). No distinct re-localization of IQGAP signals near cell leading edges was observed with
S165D-α-tubulin, which was visibly distinct from the case of DAG-lactone treatment. The
S165D expressing cells showed an overall intense IQGAP signal without distinct
compartmentalization – membrane or cytoplasmic. On further treatment with DAG-lactone,
these cells established a polar distribution of IQGAP, with stronger signals near the leading
membrane edges (Figure 3.17). However, with S165N, no changes were seen in IQGAP
localization upon further DAG-lactone treatment (not shown), similar to the untreated
condition.

3.2.3: Discussion
Our results suggest that IQGAP and E-cadherin partially overlap each other in parental or
non-migrating MCF-10A cells, as shown in the schematic diagram Figure 3.18. Upon
stimulation with the PKC activator DAG-lactone, cells acquired migratory potential
characterized by membrane ruffles comprising of localized actin polymers (filaments). This
phenomenon is also characterized by the localization of IQGAP1 (green boxes) near the
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Figure 3.17: Immunofluorescence of MCF-10A cells expressing S165D-α-tubulin (red) probed
with IQGAP1 (green) antibody and treated with Rac inhibitor NSC23766 (75 µM, 2h). This was
followed by an hour of incubation with DAG-lactone (10µM, B) or DMSO (0.05% v/v, A). The
insets show the reappearance of IQGAP signals near cell-leading edges in S165D-tubulin
expressing cells treated with and without DAG-lactone. Images were acquired at 63x objective.
Scale bar is 10 µm.

membrane periphery. Filamentous actin (F-actin) forms the docking sites for IQGAP1 in
lamellipodia of migrating cells. Upon reaching the membrane, IQGAP1 forms a tripartite
complex with β-catenin and F-actin, which helps to tether the activated Rac1 complex.
Altogether, they participate in generating a driving force that facilitates the migration of cells
by lamellipodial extensions. Inhibition of the formation of active Rac1 disrupts cell polarity
and the unique distribution pattern of IQGAP in membrane ruffles, which upon further DAGlactone treatment can be restored (Figure 3.18B).
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Figure 3.18: Schematic diagram of IQGAP1/E-cadherin expression, and subcellular distribution in
MCF-10A cells treated with DAG-lactone and/or Rac inhibitor. In a non-migrating cell or cell
cluster, IQGAP1 does not show any particular distribution domain and shares a distribution pattern
with junctional protein E-cadherin that restricts cell-migration. Momentary migratory potential
acquired by cells due to DAG-lactone treatment brings IQGAP1 near membrane ruffles or
extended lamellipodia as shown in B (marked by the dotted blue lines). Active Rac1 facilitates
IQGAP1 sequestration in the periphery of cells (Johnson et al., 2009). Actin (red dotted lines)
forms the docking sites of IQGAP1 in membrane ruffles. Upon reaching the membrane periphery
(mediated by MTs, brown lines), IQGAP1 interacts both with actins and Rac1. This distribution
pattern is also characterized by an intense signal (dark orange). A treatment with Rac inhibitor
disrupts this pattern and reverts the polarity which can be restored after activation of PKC by
DAG-lactone.
	
  

Our results indicated that the transport of IQGAP from the cytoplasmic compartment to the
cell periphery is not solely governed by the MTs. The S165D-α6-tubulin mutant did not
cause the peripheral re-distribution of IQGAP1 except at the cell-cell junctions. The fact that
S165D-expressing cells displayed IQGAP1 in lamellipodia with DAG-lactone treatment
strengthens this hypothesis. In this case, the PKC activation caused by DAG-lactone could be
promoting IQGAP phosphorylation directly and thereby brings about the re-localization of
IQGAP. In addition, there is a possible involvement of other PKC substrates which upon
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DAG-lactone-mediated phosphorylation aid in the transport of IQGAP, thereby facilitating its
subsequent interaction with active Rac1. Additionally, this complex might help in capturing
MTs near membrane peripheries, thus generating a driving force required for cell migration.
In this entire process, MTs may also act as a means to convey to IQGAP to membranes.
Further experiments need to be conducted to identify other members in this PKC-regulated
pathway of cell migration.

3.2.4: Future work
The present study has explored the possible involvement of MTs in IQGAP transport and
whether phospho-α-tubulin mediated enhanced growth duration and stability facilitate
IQGAP localization in cell-leading edges. Two approaches had been taken to address this
issue; both DAG-mediated PKC activation and phosphorylation of its substrates thereof, or
expressing the PKC substrate pseudo-phosphorylated α-tubulin. Distinct changes with
IQGAP distribution had been seen in DAG-lactone stimulated conditions, which were not
replicated upon expressing only the S165D-α-tubulin. This finding points to involvement of
other PKC substrates (including IQGAP) whose phosphorylation by PKC (upon DAGlactone treatment) participates in the IQGAP-Rac1-actin driven cell migration phenomenon.
Earlier reports had shown the involvement of Protein 4.1R, originally found in human red
blood cells, as an important component in the migration machinery of non-erythroid cells.
This protein shares a binding domain with IQGAP1 and also MTs. It acts as a membrane
anchoring protein that recruits IQGAP1 and establishes a connection between IQGAP1, actin
cytoskeleton and the plasma membrane near cell leading edges. The precise mechanism of
how Protein 4.1R is transported to the membrane periphery is not known as yet (Ruiz-Sáenz
et al., 2011). It will be interesting to study whether Protein 4.1R is a PKC substrate.
Likewise, there can be other proteins like ILK or CLASPs that are known to interact
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individually with MTs and/or IQGAPs, and might be responsible for establishing a bridge
between MTs, IQGAPs and their association with active Rac1.
MCF-10A cells provide a suitable environment for studying these interactions. They are nonmotile and express very low levels of PKC, especially PKCα. Thus they are ideal for
characterizing PKC substrates that facilitate α6-tubulin/Rac-driven enhanced cell migration.
PKC-mediated enhanced cell migration by α6-tubulin and its subsequent interaction with
Rac1 is an important finding. This calls for further attention in exploring other proteins that
interact either directly or indirectly with the IQGAP/Rac1 complex and promote cell
migration. It is possible that further elucidation of this relationship will make a significant
contribution in the field of PKC-mediated breast cancer progression.	
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Chapter 4: Interaction of MTs with MARCKS in
human breast epithelial cells

4.1: Introduction
Myristoylated-alanine-rich C kinase substrate (MARCKS), a ubiquitously expressed substrate
of PKC, has been found to be associated with adhesion, motility, neurosecretion, branching
and growth-factor-dependent mitogenesis of cells (Calabrese and Halpain, 2005); (Allen and
Aderem, 1995); (Techasen et al., 2010). MARCKS, a membrane protein, is known to bind to
the calcium/calmodulin (CaM) complex and crosslink with actin, and these activities are
regulated by phosphorylation by PKC (Allen and Aderem, 1995).
MARCKS is an acidic protein rich in alanine, glycine, proline and glutamic acid. It binds to
the membrane by the N-terminal myristoylated domain (myristoyl tail) and ionic interactions
with the acidic phospholipids by its basic effector domain (Allen and Aderem, 1995;Spizz
and Blackshear 2001). This effector domain also contains four serine residues for PKC
phosphorylation. Upon phosphorylation, MARCKS (pMARCKS) gets detached from the
membrane, localizes to the cell cytoplasm and upon de-phosphorylation, reassociates with the
cell membrane (Ottet al., 2013). MARCKS has been associated with several membranecytoskeletal events such as in binding and cross-linking of actin filaments to the membrane
(Allen and Aderem, 1995; Techasenet al., 2010) and in the dynamic remodeling of actin
filaments that is necessary for sustaining changes that occur at synaptic junctions due to
learning and development (Yarmola et al., 2001). Previous studies with fibroblasts showed
that MARCKS is associated with the lysosomal compartment upon treatment with a potent
PKC activator phorbol ester TPA (tetradecanoyl-12-phorbol-13-acetate). Upon removal of
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TPA, MARCKS is returned to the membrane in a nocodazole-sensitive manner, whereupon it
re-associates with the actin cytoskeleton. This finding implied a role for microtubules in the
recycling process of its cargo protein MARCKS (Allen and Aderem, 1995). So far, little is
known about the involvement of MTs in MARCKS transport in human breast epithelial cells.
As discussed in the previous chapter, we have shown the mechanistic significance of
phospho-α-tubulin in enhancing migration of breast cells. While MTs play a major role in
this event, they also require interactions with other membrane-bound proteins having known
functions in cell motility. MARCKS, being a substrate of PKCα and a membrane-bound
protein of known involvement in cell motility, was chosen for studying the impact of
phospho-α-tubulin on MT function. The first half of this chapter will investigate this
interaction.
Earlier from our laboratory, it had been shown that MARCKS, once phosphorylated by
PKCα, is released from the plasma membrane/cytoskeleton, and from cytoplasmic location
triggers motility in mouse melanoma F10 cells (Chen and Rotenberg, 2010). The mechanistic
significance of pMARCKS in driving cell motility was further investigated in weakly motile
F1 cells (which express low levels of pMARCKS). These cells exhibited much higher (by
three-fold) motility upon expressing a pseudo-phosphorylated form of GFP-MARCKS [four
Ser(S) residues replaced by Asp (D) residue, D/S]. When analyzed by fluorescence
microscopy, the GFP signal was found entirely in the cytoplasm. On the contrary, upon
expressing an unmyristoylated and phosphorylation-resistant (A2G_N/S) mutant of
MARCKS (localized to the cytoplasm), the overall motility was suppressed (by 40-50%) in
intrinsically motile F10 melanoma cells and metastatic MDA-MB-231 breast cells (Chen and
Rotenberg, 2010). The presence of highly active phosphatases in non-metastatic F1
melanoma cells, particularly PP1 and PP2A, resulted in the dephosphorylation of pMARCKS
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and hence accounted for their low migratory potential. Treatment of these weakly motile cells
with okadaic acid, a known inhibitor of these phosphatases, resulted in the accumulation of
WT-pMARCKS in the cytoplasm, and stimulated the migration of F1 cells. In the second
section of this chapter we investigate whether pMARCKS drives the motility alone or in an
interaction with other, presently unknown proteins.
This chapter will explore the possible role(s) of phospho-α-tubulin in MT-mediated
MARCKS transport and identify the interacting partner(s) of pMARCKS (D/S) that may
contribute to pMARCKS-driven motility of human cancer cells.

4.2: Results

4.2.1: MT-mediated cargo transport is controlled by α-tubulin phosphorylation.
The transportation of MARCKS depends on MTs (Allen and Aderem, 1995), whose
dynamics, in turn, are modulated by α-tubulin phosphorylation as we have established in
Chapter 3. Thus, herein we evaluated the impact of phospho-α6-tubulin and its mutants on
the kinetics of return of MARCKS to the membrane. We addressed this question by a twostep approach. First, we tracked and determined the rate of transport of WT-EGFP-MARCKS
with native α-tubulin in untransfected (parental) MCF-10A cells. Second, we studied the
same transport under the effect of mutants of α-tubulin in cells co-expressing WT-EGFPMARCKS and S165D/S165N-α-tubulin (in DsRed plasmids). In both cases – native and
mutants – cells were treated with DAG-lactone to activate PKCα to generate phosphoMARCKS, and the cells were fixed at different time points and inspected by fluorescence
microscopy. The effect of phosphorylation of α-tubulin on MARCKS transport was analyzed
by measuring the differential distribution of WT-GFP-MARCKS between its two cellular
domains – at the cell periphery and in the cytoplasm.
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Figure 4.1: Transport of MARCKS in MCF-10A cells expressing α6-tubulin mutants. Cells were
transfected with WT-GFP-MARCKS (native condition) alone or along with S165D/N mutants of
α6-tubulin in DsRed plasmid. Cells were treated with 10 µM DAG-lactone for 1 h, followed by
wash-out with PBS and fixation at the various time points shown. The zero time point represents
the state prior to DAG-lactone treatment. Cells expressing either WT-GFP-MARCKS (green)
signals or mutants of α-tubulin along with WT-GFP-MARCKS (dual signals (Red for the mutants
of α-tubulin and green for WT-MARCKS) were selected. Here, only the images from the green
channels had been shown. Images were acquired by 63x oil immersion lens. Scale bar is 10 µm.
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Figure 4.2: The phosphorylation-resistant mutant (S165N) of α6-tubulin slows the rate of transport
of MARCKS to the plasma membrane. MARCKS localization at each time point under the three
different conditions of α-tubulin (native α-tubulin, S165D-α-tubulin and S165N-α-tubulin) is
quantified by analysis of the set of images from Figure 4.1. The metric is the normalized
differential intensity, i.e., the average fluorescence intensity at the cell periphery (+ y axis) minus
that in the cytoplasm (- y axis) divided by the total intensity in the cell. For each time point, at
least 10 cells were analyzed, and the results are statistics from three independent experiments.

In Figure 4.1 we tracked WT-GFP-MARCKS transport qualitatively. For each condition,
Figure 4.2 graphically shows the relative distribution of MARCKS characterized by the
normalized differential intensity, i.e., the average fluorescence intensity at the cell periphery
minus that in the cytoplasm divided by the total intensity in the cell. Thus, a value of zero in
Figure 4.2 indicates an equal distribution of MARCKS in the two compartments. Following a
1 h treatment with DAG-lactone and subsequent wash-out, the fluorescence signal was
detected almost entirely in the cytoplasm and hence the normalized values were negative.
Following the addition of DAG-lactone (at t = 0) and subsequent wash-out with PBS buffer
(at t = 1 h), in general the MARCKS signal localized in cytoplasm. Its return to the
membrane was tracked over time by fixing cells at different time points between 1 h and 15 h
(Figure 4.2). In native conditions, WT-MARCKS upon phosphorylation was detached
completely from the cell membrane and after 1 h; it had localized to the cell cytoplasm near
the perinuclear regions. Following DAG-treatment and its removal from the medium
(Methods), WT-MARCKS was seen to relocate from the cytoplasmic pool to the cell
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periphery. This path of WT-MARCKS transport from membrane à cytoplasm à membrane
is made apparent in Figure 4.2. It was observed that from 4 hours and onwards, MARCKS
was transported to the membrane, the entire process of translocation required 15 h post-DAG
treatment.
The same experiment was carried out with MCF-10A cells that co-expressed EGFP-WTMARCKS and either the S165D or the S165N mutant of α6-tubulin. Only those cells that
expressed both green (EGFP-MARCKS) and red (DsRed plus the α6-tubulin mutant) signals
were selected for the analysis. Cells from the same dish that did not express the red color
(mutants) but only GFP-MARCKS were used as convenient negative controls, and the rate of
pMARCKS movement was compared to the native α-tubulin condition.
Since cells had been stimulated with DAG-lactone to cause release of MARCKS due to
phosphorylation, native α-tubulin would also have undergone phosphorylation under these
conditions. Thus, expression of the S165D mutant displayed a kinetic pattern of EGFPMARCKS translocation that was similar to that produced by the native α-tubulin (Figure 4.1
and Figure 4.2). Around 6 h post-DAG-lactone treatment, cells expressing S165D displayed
equivalent localization of WT-GFP-MARCKS – both in the cytoplasm and the membrane,
and was similar to that of parental cells expressing EGFP-MARCKS. Because this
experiment required DAG-lactone to generate the reversibly phosphorylated WT-MARCKS,
native α-tubulin would have undergone phosphorylation and hence the S165D α6-tubulin
mutant expression produced similar results to that of the native condition. In contrast,
expression of the S165N mutant dramatically slowed translocation of EGFP-MARCKS as
evident from the insignificant change in the location of the EGFP signal up to 6 h. Cells
displayed equivalent localization between cytoplasm and membrane at approximately 14 h
and complete recovery of membrane-associated MARCKS from the cytoplasm was not
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Figure 4.3: Western blot of cell lysates prepared from MCF-10A cells transiently expressing D/S,
and A2G_N/S_MARCKS in TAPA vector. Empty vector in MCF-10A cells (VC) and F10 cells
were used as corresponding negative and positive controls respectively. Expression of MARCKS
(near 80 kDa) was confirmed by probing with anti-MARCKS antibody (1:2,500). At least three
subclones were selected and confirmed by western blot. One such clone of D/S MARCKS (5) is
shown here along with three subclones of A2G_N/S_MARCKS, of which clone 1 A2G_N/S was
used in the experiments.
	
  

achieved by 14-15 h (Figure 4.1) but required even longer times (around 22-24 h, not shown)
as depicted in Figure 4.2. A slower rate of transport and recovery of WT-GFP-MARCKS to
the membrane due to expression of S165N-α6-tubulin thus confirmed the significance of
phosphorylation of α-tubulin at Ser-165 for efficient functioning of MTs in a transport
process.

4.2.2: Identification of D/S MARCKS-binding proteins by a tandem affinity method of
protein purification (TAP)
Our laboratory has demonstrated that a pseudo-phosphorylated MARCKS mutant (D/SMARCKS) that resides in cytoplasm stimulates motility in mouse melanoma cells (Chen
and Rotenberg, 2010). The role of cytoplasmic pMARCKS in motile behavior was further
explored by constructing a double mutant (A2G_N/S), which was both phosphorylationresistant and unmyristoylated, hence cytoplasmic. Non-motile MCF-10A cells express very
low levels of MARCKS (see Figure 4.3), and therefore provide an ideal model to study the
binding partner(s) of pMARCKS that altogether participate in cell migration. The pseudophosphorylated D/S_MARCKS was chosen for this purpose. In addition, the A2G_N/S
mutant was used as a negative control since it cannot undergo phosphorylation.
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Figure 4.4: Schematic diagram of tandem affinity chromatography purification of protein of
interest and interacting proteins using streptavidin and calmodulin resins (Agilent Technologies).

To investigate new proteins interacting with pMARCKS, the full-length D/S_MARCKS gene
(~1.086 bp) was inserted in a TAP vector. This vector (~4.5kb) is specifically used in the
TAP method for the purpose of purifying protein complexes using two affinity tags –
streptavidin binding peptide (SBP) and calmodulin binding peptide (CBP). The Tandem
affinity method of protein purification (TAP) permits the isolation of affinity-tagged
MARCKS along with any proteins bound to it under non-detergent conditions that preserve
these protein-protein interactions. Following affinity chromatography on the two resins, the
eluate is analyzed by tandem mass spectrometry (MS/MS) in order to identify potential
binding partners of MARCKS. As described in the Methods, D/S_MARCKS, and A2G_N/S
MARCKS were cloned in-frame to pCTAP vector such that the affinity tags were at the C-
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Figure 4.5: Purification of proteins interacting with D/S MARCKS by TAP method. MCF-10A
cells were transfected with empty vector (VC), D/S_MARCKS or A2G_N/S_MARCKS. (A)
Western blot of 10-µl aliquots of lysates prepared from cells expressing TAP-MARCKS proteins
(100 µg lysate per well) and developed with anti-MARCKS (1:1000, Cell Signaling Technology).
(B) TAP-purified MARCKS proteins and their protein binding partners were resolved in an 8%
SDS-PAGE gel (having 0.75 mm thickness) and the gel was stained with GelCode Blue. A gel
(representing three independent experiments) shows bands between 48-80 kDa that were unique to
D/S_MARCKS. The gel bands were excised and sent for mass spectrometric analysis. (C) MS/MS
results are shown in the accompanying table that identified several potential protein-binding
partners.

terminus of the MARCKS gene. At least three clones for each condition were selected and
expressed in MCF-10A cells for confirming the expression of proteins. Lysates prepared
from F10 cells and empty vector were used as positive and negative controls respectively.
Bands around ~75-80 kDa were detected for MARCKS (Figure 4.3). Next, one clone from
each of the two constructs was expressed in MCF-10A cells for purifying the proteins using
TAP method. Lysates were prepared from 80-90% confluent 10-cm dishes by freeze-thaw
method, followed by an extended duration of protein purification and final sample
preparation using the manufacturer’s protocol (InterPlay Mammalian TAP System, Agilent)
as described in Methods. A schematic diagram of the method is shown in Figure 4.4.
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The samples were resolved in an 8% SDS-PAGE gel of 0.75 mm thickness and stained with
Gel Code Blue. In Figure 4.5A, distinct bands are observed between 50 and 75 kDa; these
were unique to D/S-MARCKS and absent in either vector control or A2G_N/S_MARCKS.
The phosphorylation-resistant and unmyristoylated mutant (A2G_N/S_MARCKS) was
chosen as a control in this experiment, since, like the pseudo-phosphorylated D/S form, it
resides completely in the cytoplasm due to the absence of the myristoyl group that anchors
native MARCKS to the membrane. Bands unique to D/S-MARCKS (see Figure 4.5B) were
excised from the gel and sent for protein identification by mass spectrometry. The results are
presented in Figure 4.5C.

4.3: Discussion
In the previous chapter phosphorylation of α-tubulin (PKC substrate) was shown to drive
migration of breast cells. Cell migration is a complex process that requires interplay of
several proteins located in the membrane, cytoplasm, and cytoskeleton to generate the driving
force for forward cell movement. One functional aspect of phosphorylation of α-tubulin was
studied by its interaction with membrane-bound proteins like Rac1 and IQGAP1, both of
which are associated with cell migration (Waterman-Storer et al., 1999); (Jadeski et al.,
2008). Another aspect of this phenomenon was illustrated in this chapter by exploring the
interaction of MTs with a PKC substrate, the MARCKS protein. It had been shown earlier
that the conventional isoforms PKC-α, novel PKC-ε and PKC-θ (but not the atypical forms)
phosphorylate MARCKS in NIH3T3 fibroblasts (Kampfer et al., 1998).
During its transient interaction with the cytoskeleton, MARCKS regulates F-actin dynamics
that in turn impacts cell surface activities such as cell migration, exocytosis, and endocytosis
(Arbuzova et al., 2002). Following its release from the membrane due to phosphorylation,
phosphoMARCKS (pMARCKS) associates with the MTOC (Friedl and Brocker, 2000) and
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promotes motility of different cancer cells (Chen and Rotenberg, 2010). Its transport back to
the membrane is dependent on dephosphorylation (Chen and Rotenberg, 2010), and the
cargo-transporting machinery that is a part of MTs (Allan and Aderem, 1995). While
phosphatase PP2A activity is known to dephosphorylate pMARCKS (Clarke et al., 1993) and
has been detected on the MT surface (Meisinger et al., 2003), the chronology of events that
enable the interaction of MARCKS with MTs remains unexplored.
Previous experiments with pMARCKS and its role in motility were conducted in both nonmotile F1 and highly motile F10 mouse melanoma cells (Chen and Rotenberg, 2010). In both
cell lines, the most abundantly expressed form of PKC is its α-isoforms, and migration and
invasion of both cell lines is driven by on PKCα-activity. Though the F1 cells (a related cell
line of F10) express high levels of PKCα. However due to active PP2 phosphatases, there is
an undetectable level of pMARCKS in these cells that accounts for their low motility. To
study the effect of phospho-α-tubulin on MARCKS transport, we needed an environment that
has low basal levels of PKC and MARCKS. This low background will help to discern the
obvious effects of the PKC-driven pathway. MCF-10A cells were therefore chosen for this
purpose as these non-motile cells express very low levels of both PKC and MARCKS.
Our current study led to the interesting observation that MT-mediated transport of MARCKS
(and presumably other cargo proteins) is strongly controlled by the phosphorylation state of
Ser-165 in α-tubulin. This finding suggests an interesting choreography of PKC whose
activation involves phosphorylation of its substrates – MARCKS and α-tubulin – both having
their characteristic roles in cell migration. Therefore, PKC activity would cause the release of
MARCKS from the membrane while simultaneously activating the α6-tubulin-mediated MTmachinery required for its efficient return.
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MARCKS is a substrate for G1 kinases, cdk 4/6 and PKCs. Hence, being common to both
PKC and cell-cycle signaling pathways, MARCKS is an attractive target for studying the
functioning of these pathways in cells. Previous studies reported that breast cancers, chiefly
ER-negative cells, express high levels of MARCKS (Browne et al., 2013). Since elevated
PKCα expression can also be associated with breast cancer progression, it will be worth
targeting other proteins interacting with MARCKS in its phosphorylated form that would
promote cell migration.
The Tandem Method of protein purification has emerged as a powerful tool by which to
isolate and purify the protein complexes bound to the protein of interest from cell lysates.
Using this approach, we identified three strong bands between 50-75 kDa that were unique to
the

pseudo-phosphorylated

MARCKS

(D/S_MARCKS).The

unmyristoylated,

phosphorylation-resistant MARCKS (A2G_N/S_MARCKS) was an ideal control for this
experiment, because, like the D/S mutant, it resides completely in the cell cytoplasm due to
the absence of a myristoyl tail. In TAP, proteins that usually associate with pMARCKS in
vivo would bind the phosphorylation sites in pMARCKS. The eluted fraction purified
successively with by two affinity columns contain those proteins that solely recognized the
phosphorylated form of MARCKS having an intact myristoyl tail (D/S). One or more of these
proteins may play a crucial role in driving cell migration by interacting with pMARCKS.

4.4: Future work
Further progress may be made by identifying and characterizing each of the interacting
proteins of D/S-MARCKS. It will be interesting to know whether any of those identified
protein(s) is a PKC substrate, and whether they have any role in PKC-mediated pathway of
cell signaling. Experiments can be designed accordingly to investigate the roles of protein
binding partners in pathways promoted by pMARCKS.
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Based on the identification, a site-specific mutation in the identified protein at a cationic site
that recognizes the phosphorylation-site domain of MARCKS will help to identify its role.
By constructing site-specific mutants or knockdown of the respective protein by smallinterfering RNA (siRNA) methodology, the impact on cell migration by a binding protein
may be assessed. If any of the identified proteins is a PKC substrate, then its mutant forms
can be used to study the phenotypes by using any PKC activator (like DAG-lactone) in nonmotile cells (like MCF-10A) that express low levels of PKC, or by using a PKC inhibitor
(e.g. BIM) in metastatic cells.
For reasons mentioned in previous sections also, MCF-10A cells serve as an ideal
intracellular setting to characterize the functionality of any of the identified proteins
interacting with pMARCKS. Besides characterizing the expression profiles of binding
partners with the wild-type or mutants by Western blot, immunofluorescence experiments
can be carried out to study their distribution pattern in cells. Immunofluorescence with fixed
cells or live-cell imaging of fluorophore-tagged proteins, and quantitation of average signal
intensity, will help to characterize localization patterns both qualitatively and quantitatively.
Proteins bound to cytoplasmic pMARCKS can be tagged to any fluorophores (EGFP or RFP)
and a time course study can be conducted monitoring the return of pMARCKS under various
conditions of the protein – wild-type or mutants (gain-of-function or loss-of-functions). It
will be interesting to know whether any of them alter the rate of return of pMARCKS besides
the known contribution of phospho-α-tubulin as shown in this chapter.
Several other experiments can be conducted to study the basic phenotypic changes in cells
upon expressing the mutants – such as assays of cell motility, proliferation, invasion, and
apoptosis. Furthermore, the involvement of the MARCKS binding partners in the cell cycle
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can be studied by analyzing DNA and BrdU levels, or by the FUCCI cell cycle sensor (Life
technologies).
Additionally, with the accelerating improvements in imaging techniques, interaction between
proteins, membrane or cytoplasmic, can be carried out by an extensive in-vivo imaging based
on differential staining methods, using fluorophores or FRET. A three-dimensional
characterization of the proteins and their influences in acini formation, alongside staining
with known biomarker proteins, may be carried out. This can be performed reliably with
stable expression of proteins. An alternate to the 3D work in Matrigel is generating
microtissues or microspheroids in non-adhesive hydrogels, and allowing the monitoring of
morphometric changes in shape, size, proliferation or viability (Napolitano et al., 2007).
Imaging followed by analysis using software like MetamorphTM, Imaris Bitplane or ImageJ
will help to shed light on the in vivo machinery related to cell signaling and migratory
pathways.
To summarize, the identification of interacting partners of pMARCKS is an important query
that will help to elucidate the roles of PKC and pMARCKS in breast cancer progression.
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Chapter 5: Characterization of α-tubulin mutants in
normal and malignant breast epithelial cells

The two mutants of α-tubulin – S165D and S165N have been characterized by the following
approaches in normal (MCF-10A) and malignant (MDA-MB-231) breast epithelial cells –
three-dimensional growth assay, migration assay, and two-dimensional morphology study by
staining, along with confirmation using western blot.

5.1: Three-dimensional study

5.1.1: Introduction
The mammary gland of an adult breast is composed of ducts and lobules. The ducts end in a
highly branched structure known as terminal ductal lobular unit (TDLU), which is made up
of numerous individual acinar units. A mammary acinus is characterized by a central hollow
lumen surrounded by a single layer of polarized epithelial cells, and myoepthelial cells
attached to an underlying basement membrane (Figure 5.1) (Debnath et al., 2003). The
development and maintenance of this well-organized polarized structure is critical for the
formation and functioning of epithelial cells, disruption of which results in pathogenesis of
epithelial tumors known as carcinomas. Filling of the hollow luminal space is a distinct
feature of early epithelial tumors, such as atypical hyperplasia and ductal carcinoma (Debnath
et al., 2002).
Studies involving primary human tumors and mouse models of epithelial tumors have
provided valuable information on the genetic events associated with carcinoma formation
(Debnath et al., 2003). However, those models are not particularly well suited for studying
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Figure 5.1: Morphological architecture of an MCF-10A acinus. (A) Schematic diagram of a human
mammary epithelial gland. The mammary gland has a polarized architecture with a central hollow
lumen (marked by arrow) which is surrounded by luminal epithelial cells (inner layer), followed
by basal epithelial and myoepthelial cells anchored to basement membrane (Debnath et al., 2003).
(B) Bright field image of an acinus on the 8th day of growth on Matrigel; the luminal region has
been marked with a black arrow. From day 9 onwards the central region of the acinus is
characterized by a hollow lumen.

the underpinning signaling pathways that are involved in tumor formation and early
oncogenesis. Although monolayer cells are used to study the biochemical pathways
pertaining to tumor formation, they do not fully reproduce the glandular structures. Hence,
the monolayer cells do not provide a complete understanding of the molecular mechanisms
that are affected during tumor progression that lead to the disruption of the well-defined
glandular structures.
Three-dimensional (3D) cultures provide a unique platform to model the in vivo breast
glandular structure, allowing the characterization and investigation of the biochemical events
involved in the morphogenesis of glandular epithelial structures. Since mammary epithelial
cells grown in 3D matrices mimic numerous features of breast epithelium in vivo, 3D-culture
provides an opportunity to determine the mechanistic pathways that lead to the disruption of
the well-organized glandular architecture by cancer genes. It has been found that the external
matrix plays a significant role in the maintenance of tissue specificity of malignant or nonmalignant mammary cells (Kenny et al., 2007). The epithelial cells as well as other
differentiated cells lose many aspects of their differentiated states upon growing as a
monolayer on a culture dish. However, when grown in a three-dimensional basement
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membrane culture, epithelial cells form glandular acini retain several aspects of the glandular
architecture in vivo. Thus, 3D-culture of cells has undoubtedly emerged as a powerful tool to
characterize the molecular events in breast and other cancers. This technique deals effectively
with the limitations imposed by monolayer cell cultures, mouse model or human tissues.
Earlier chapters have described the mechanism by which phosphorylation at Ser-165 residue
on α6-tubulin contributes to enhanced migration in breast cells. The phosphorylation of α6tubulin has two primary functional consequences. It enhances cell migration by an increased
activation of Rac1 near lamellipodial extensions of migrating cells by elongated, stable and
dynamically active MTs (Chapter 3). Furthermore, phospho-α6-tubulin (which was studied as
the pseudo-phosphorylated S165D mutant) aid in the transport of membrane-protein
MARCKS whose phosphorylation confers cell motility (Chapter 4). In contrast, the phosphoresistant mutant form (S165N) when expressed in cells, exhibited a sedentary behavior of
MTs and a slower rate of cargo protein-MARCKS transport. Two immediate questions that
arise from these studies are: (1) how do the mutants of phospho-α-tubulin behave in vivo, and
(2) how does phosphorylated-α-tubulin and enhanced MT dynamicity affect the glandular
morphogenesis of breast cells?
These questions therefore prompt us to study the breast cells by an approach that is not
encumbered by the limitations of monolayer cultures or tissue samples, but allows us to
characterize breast glandular structures under conditions of phospho-α-tubulin expression.

5.1.2: Results
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5.1.2.1: Characterization of WT α-tubulin in MCF-10A mammary epithelial acini by
DAG-lactone treatment
The non-transformed, non-tumorigenic, immortalized MCF-10A cells attain a cobblestone
like morphology when grown as a monolayer on plastic culture dishes. When grown on a
reconstituted basement membrane in 3D culture, they attain a polarized, growth-arrested,
rounded morphology (Debnath, et al., 2003).
MCF-10A cells were seeded at a density of 3x103 cells per well of a 96-well plate or 16-well
chamber slide pre-coated with a thin layer of Matrigel (Methods). Cells were grown in a 2%
reduced serum assay medium for 10-12 days, and the media was changed every 2 days. For
analyzing the effects of DAG-lactone on the acinar structures, MCF-10A cells were
incubated with DAG-lactone (10 µM) in Matrigel for ~1-2 hrs every other day from Day 4.
Bright field images were taken on alternate days for ~10-12 days. At the end of a 12-day
assay, nuclear staining was performed to study the morphology of the MCF-10A acini.
As shown by multiple studies, (Debnath et al., 2002, Debnath et al., 2003; Lee et al. 2007),
MCF-10A cells acquire a growth-arrested acini-like spheroidal structure with a central
hollow lumen surrounded by a single layer of epithelial cells (Figure 5.1). In the cascade of
proliferative and morphogenetic events, the cells that are in direct contact with the basement
membrane arepolarized prior to the formation of a central lumen in the acini. Once the
apicobasal polarity is established, the centrally located non-polarized cells that are not in
direct contact with the basement membrane are cleared by apoptosis resulting in the
formation of a central hollow lumen. This engenders further growth (proliferation) of cells
during acinar development. Thus, apoptosis maintains a luminal space within a growtharrested, well-defined acinar structure of normal mammary epithelial cells (Debnath et al.,
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(A) MCF-10A Control, Day 8+

(B) MCF-10A + DAG, Day 8+

(C) MCF-10A Control, Day 12+

(D) MCF-10A + DAG, Day 12+

Figure 5.2: Morphology of acinar structures formed by MCF-10A cells in Matrigel. The images
were taken at timepoints between 12-15 days (A, B) with a 10x objective. The acini were treated
with DAG-lactone (10 µM) or DMSO (0.05% v/v) on every alternate days for an hour. Phase
images of an acinus with and without DAG-lactone treatment at higher magnification (63x) on
Day 12 are shown in the lower panel (C, D). The acini were labeled with the nuclear stain Hoechst.
Results are representative of two independent experiments. Scale bar is 50 µm top panels, 25 µm
bottom panels.

2002). Disruption of a well-defined structure along with filling of the central lumen together,
results in carcinoma formation.
Our preliminary experiments with untreated MCF-10A acinar structures showed a welldefined rounded morphology, while the colonies exposed to DAG-lactone treatment showed
lobular mass-like structures with disrupted basement membranes (Figure 5.2A, B) at the end
of the 12-day assay. Colonies stained with Hoechst nuclear stain followed by confocal
imaging revealed their morphogenetic features. Untreated parental MCF-10A cells exhibited
well- organized rounded structures that were comprised of a central hollow lumen surrounded
by basally localized epithelial cells (Figure 5.2C). Strikingly, the cells that were treated with
DAG-lactone developed a globular mass-like structure that contrasted with the round acini of
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the control MCF-10A cells (Figure 5.2D). The acinar units produced during DAG-lactone
treatment somehow lacked a well-defined structure and a proper central hollow lumen.
In our live cell imaging and partitioning experiments, a strong effect by DAG-lactone on the
behavior of MTs in MCF-10A cells was demonstrated (Chapter 3). Under conditions of
DAG-lactone treatment, PKC isoforms phosphorylate multiple substrates, one of which is αtubulin. Additional substrates phosphorylated by PKC may act in concert with phospho-αtubulin, and thereby promote cell migration and proliferation during different stages of
morphogenesis. However, our preliminary results with MCF-10A cells growing in a 3Denvironment with DAG-lactone were inconclusive. To elucidate further the role of α-tubulin
in determining acinar morphology, characterization of cells expressing the S165D or S165Nα6-tubulin mutant in a 3D-Matrigel was required.

5.1.2.2: Characterization of S165D and S165N-mutants of α-tubulin of MDA-MB-231
acini
For a better understanding of the effect of mutants of α-tubulin on acinar morphogenesis,
highly metastatic breast epithelial MDA-MB-231 cells stably expressing the two mutants –
S165D and S165N-α-tubulin, were grown in a 3D-Matrigel. Therefore; the results represent
the behavior of a uniform population of cells that all express a given mutant, in contrast with
the heterogeneity of transient expression. 	
  
Unlike the parental MCF-10A cells, parental MDA-MB-231 cells (or cells transfected with
the empty pcDNA-myc vector) exhibited a stellate-like morphology in a 3D matrix (Kenny et
al., 2007). The stellate morphology was well-distinguished from rounded colonies by the
occurrence of disorganized nuclei, elongated cell bodies, and stellate-like protruding
projections often bridging multiple cell colonies in a 3D matrix. Figure 5.3A shows MDA-
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A. Vector Control-231 cells in 2D (monolayer culture)

B. Vector Control-231 cells-Day 2

C. Vector Control-231 cells Day 4

D. Vector Control-231 cells Day 6

E. Vector Control-231 cells Day 10

Figure 5.3: Morphology of MDA-MB-231 colonies grown in 3D-Matrigel. The top panel (A)
shows MDA-MB-231 cells when grown in a monolayer culture at a low seeding density. Panel B
through E shows gradual changes in the morphologies of MDA-MB-231 colonies when grown in a
3D-Matrigel (seeding density 2x103 /well) for 10 days. Bright field images of the colonies were
taken by 10X objective. Results are representative of four independent experiments.

MB-231 cells (expressing the empty vector) in a monolayer culture when seeded at a low
density (top panel). When grown in a 3D-Matrigel (Figure 5.3B-E), these cells undergo
gradual changes in morphology as observed by bright field images taken on different days of
the assay. The structures showed invasive phenotypes with star-like morphologies formed by
clusters of cells.	
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A. S165D-myc-231 cells in 2D (monolayer culture)

B. S165D-myc-231 cells Day 2

C. S165D-myc-231 cells Day 4

D. S165D-myc-231 cells Day 6

E. S165D-myc-231 cells Day 10

Figure 5.4: Morphology of MDA-MB-231 cells expressing S165D-α6-tubulin and grown in
monolayer culture. The top panel (A) shows S165D-α-tubulin stably expressing MDA-MB-231
cells when grown in a monolayer culture at a low seeding density. Panel B through E shows
gradual changes in the morphologies of S165D colonies when grown in a 3D-Matrigel (seeding
density 2x103/well) for 10 days. Bright field images of the colonies were taken by 10X objective.
Results are representative of four independent experiments.

The stable MDA-MB-231 cells expressing pseudo-phosphorylated-α6-tubulin mutant
(S165D) formed grape-like structures when grown in a 3D-Matrigel. This structure is
characterized by the formation of multi-acinar structures, disorganized nuclei and tight cellcell adhesions. Figure 5.4B-E show the gradual morphological changes of S165D-α6-tubulin231 cells grown in a 3D-matrix before attaining rounded, large multi-acinar clumps and
contrast dramatically with cells grown as a 2D monolayer (Figure 5.4A). On the other hand,
the S165N mutants displayed much smaller mass-like structures from day 1 to 4 before
96
	
  

	
  
	
  

A. S165N-myc-231 cells in 2D (monolayer culture)

B. S165N-myc-231 cells Day 2

C. S165N-myc-231 cells Day 4

D. S165N-myc-231 cells Day 6

E. S165N-myc-231 cells Day 10

Figure 5.5: Morphology of MDA-MB-231 cells expressing S165N-α6-tubulin and grown in
monolayer culture. The top panel (A) shows S165N-α-tubulin stably expressing MDA-MB-231
cells when grown in a monolayer culture at a low seeding density. Panel B through E shows
gradual changes in the morphologies of S165N-231 colonies when grown in a 3D-Matrigel
(seeding density 2X103/well) for 10 days. Bright field images of the colonies were taken by 10X
objective. Results are representative of four independent experiments.

forming a semi-lobular rounded morphology having some small invasive protrusions (Figure
5.5). Mass-like structures are characterized by circular colony outlines but differ from the
“round morphological grouping” by their disorganized pattern of nuclei and filled luminal
regions (Kenny et al., 2007).
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NUCLEAR STAIN (HOECHST)

BRIGHT FIELD

A. MDA-MB-231 cells (vector control)

B. S165D-α-tubulin-231 cells

C. S165N-α-tubulin-231 cells
Figure 5.6: Morphology of acinar structures formed by MDA-MB-231 cells expressing α6-tubulin
mutants in 3D culture. Mutant (S165D and S165N expressing) or vector control cells were
cultured in Matrigel for 8-10 days. The Hoechst stained (left) and bright field (right) images of the
3D-structures from day 8 are shown. Optical sections (central z) with maximum intensity
projections of representative colonies for cells of different conditions are shown here. The results
are representative of three independent experiments. Scale bar is 100 µm.

Further analyses of these structures were conducted by staining them with the nuclear stain
Hoechst on day 8. As shown in Figure 5.6B, S165D-expressing cells formed large, compact
multi-acinar and multi-nuclear assemblies. Some also formed large grape-like round clusters
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Figure 5.7: The average number of nuclei per 3D assembly for cells expressing each α6-tubulin
mutant. Results were obtained from MDA-MB-231 cells stably expressing either S165D or
S165N-α-tubulin, or the vector control (VC) from Figure 5.6 are shown graphically. An unpaired
Student’s t-test was used to determine the statistical significance between the mutants and the
control ( p<0.001, *	
  p<0.0001).
+

(data not shown). Interestingly, the S165N-cells exhibited somewhat smaller mass-like
structures with fewer nuclei per assemblages (Figure 5.6C). Overall, their colonies were
much smaller in size and the cells displayed somewhat poor cell-cell adhesions. They were in
stark contrast with control 231cells which formed multi-nuclear discrete clusters with
disorganized morphologies, where some cells displayed protrusions that bridged multiple cell
colonies (Figure 5.6A).
Optical sections of each of these clusters were analyzed for counting nuclei-per-assembly by
ImageJ (3D object counter). The results reported in Figure 5.7 are the nuclei counts per
cluster formed in each condition. The average number of nuclei per cluster is significantly
higher in S165D-expressing 231-cells (p<0.005) compared to S165N and the parental cells
(p<0.05). These values correlate with the sizes of multi-acinar structures as well. These
results indicate that with the pseudo-phosphorylated α-tubulin mutant, 231 cells acquire
features that improve cell-cell adhesion thereby forming large multinucleated multi-acinar
tight complexes. These features are strikingly similar to MCF-10A cells over-expressing the
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oncogene ErbB2 that results in the filling up of the central hollow lumen by an enhanced cellproliferation and formation of lobular grape-like tight acinar structures (Debnath et al., 2002).
The control 231 cells, on the other hand, formed multinucleated structures but lacked an
overall integrity in them. Thus, they produced discrete structures that lacked tight cell-cell
contacts and well-defined acinar boundaries. The phosphorylation-resistant S165N mutants
formed relatively smaller masses with fewer nuclei per aggregation. When grown for 10 to 12
days, cells expressing the S165N mutant resembled parental 231 structures in 3D Matrigel
and lacked the large multi-lobular appearance produced by the S165D mutant. The seeding
density of cells in 3D Matrigel largely governs the formation of these structures. For all the
experiments performed above, the seeding density had been typically set around 2.5-3x103
cells per well and the cells were maintained at identical conditions.	
  

5.2: Migration assay
In addition to the three-dimensional growth assay, the stable transfectants of MDA-MB-231
cells were also characterized quantitatively for their migratory potential. This experiment was
performed with the stable expression of each mutant of α6-tubulin.
The cells were seeded as tight concentric circles on a 10-well glass slide pre-coated with 1%
BSA by a cell-sedimentation manifold. After an overnight incubation, the images for each of
these circles were taken, followed by another image acquisition after 6 h. The difference in
the areas of the circles indicated the migration of cells within the incubation time (6 h) and is
plotted graphically in Figure 5.8A. Our results show that 231 cells stably expressing the
S165D-α-tubulin mutant exhibit a much higher migration value (by 90%, p<0.005) when
compared to cells expressing the S165N mutant. However, S165D-expressing cells were
more motile by only 35-40% (p<0.05). The effect of the pseudo-phosphorylated mutant on
cell migration was muted to a certain extent in because metastatic 231 cells are already highly
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motile. The effect of S165N on cell migratory potential is of particular importance here. In
chapter 3, our in-vivo imaging with these cells transiently expressing S165N (and MTdynamicity calculations thereof) had shown the effect of this mutant on suppression of the
overall motile behavior of MTs. This mechanism therefore led to a reduced migratory
potential that is now strongly evident from the migration results as presented in Figure 5.8A.
We next investigated the effect of Rac1 inhibitor (NSC23766) on the migration of cells
expressing S165D and S165N-mutants of α-tubulin. In chapter 3, we had seen that the
elongated and stable MTs composed of S165D-α6-tubulin led to an increased activation of
Rac1 in an unknown mechanism, which participated in a concerted event of enhanced cell
migration. We hypothesized that the stable MTs composed of phospho-α-tubulin, sustain
activated Rac1 near cell periphery for a relatively long time, thereby continuing accelerated
cell migration. An active Rac1 (GTP-bound) is essential for this process, inhibition of which
will result in reduced cell migration. Rac1 inhibitor (NSC23766) prevents the formation of
Rac1-GTP, therefore, will result in reduced cell migration. Our results of MDA-MB-231
transiently transfected with S165D, S165N-α-tubulin or empty vector (vector control, VC)
upon treatment with the Rac1 inhibitor (50µM, 6hrs) showed that the S165D-mutant had
minimum effect of the inhibitor on cell migration. As shown in Figure 5.8B, the S165Nmutant or the vector control cells suffered greatly (~ 50%) from reduced migration upon
treatment with Rac1 inhibitor compared to the S165D-mutant. This is also reproduced with
the stable cells expressing S165D, or S165N-α-tubulin. This indicates that cells expressing
S165D-α-tubulin resulted in relatively stable MTs that sustained active Rac1 near cell
periphery, hence, less tolerant to the Rac inhibitor.
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Figure 5.8: (A) Motility of MDA-MB-231 cells stably expressing α6-tubulin mutants. MDA-MB231 cells expressing either the mutant α6-tubulin or the vector control (VC) were plated on 10well glass slide and incubated overnight at 37°C and 5% CO2. Images were acquired by a 4X
objective at t = 0 and t = 6 h time points. The differences in the areas of the circles occupied by the
cells between the two time intervals indicate their migration and had been plotted graphically.
Student’s t-test has been used to measure the statistical significance between the mutants and their
+
corresponding control ( p<0.001, * p<0.0001) with n= 9-11, where n = number of concentric
circles measured per condition. (B) Motility of MDA-MB-231 cells transiently transfected with
S165D, S165N-α-tubulin along with the corresponding vector control. Cells were treated with Rac
inhibitor (NSC23766, 50 µM in water) for 6h. Images were acquired by 4x objective at t = 0
and t = 6 h time points. The differences in the areas of the circles occupied by the cells between the
two time intervals were plotted graphically along with their untreated conditions. Student’s t-test
was used to measure the statistical significance between the mutants and their corresponding
+
control ( p<0.01, ^ p<0.02, * p<0.05) with n= 6-9, where n = number of concentric circles
measured per condition.
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5.3: Morphology study in 2D
IQGAP1 is one of the major proteins in the signaling pathways that have been known to
stimulate cell proliferation and promote tumorigenesis in human breast epithelial cells.
Amongst known breast epithelial cells, highly metastatic MDA-MB-231 cells express
significantly high levels of IQGAP1 (Jadeski et al., 2008). Earlier in this chapter we have
shown the different morphological features of glandular structures formed by stably
expressing S165D/N mutant-231 cells when grown in 3D-Matrigel. While the parental cells
showed invasive properties of tumors, the S165D mutants formed larger mass, solid tumorlike structures. On the other hand, the S165N mutants displayed smaller masses lacking
invading protrusions. In this section, the expression level and the distribution pattern of
IQGAP1 with these mutants of α-tubulin was studied in stably transfected 231 cells. Note
that in chapter 3, we did not find a definite link between IQGAP1 and transiently expressing
α-tubulin S165D/N MCF-10A cells. In the investigation reported below, we re-address this
issue with stably expressing mutants in metastatic MDA-MB-231 cells.
The cells expressing S165D/N or the empty vector were grown on glass coverslips, fixed
with 3.7% PFA and 0.5% glutaraldehyde before staining with IQGAP1 or Cell-Mask stain to
study the morphology of cells. Control 231 cells displayed strong IQGAP1 signals near
membrane ruffles in Figure 5.9A, which correlated with cell motility. Some IQGAP1 signals
were also seen near perinuclear regions. In general, the S165D mutant expressing cells had
elongated morphology compared to control 231 cells, and displayed sharp protruding spikelike structures. On the contrary, the S165N mutants resulted in a stubby appearance having
fewer protrusions (see Figure 5.9B). The morphological features of these cells were
quantitatively analyzed by the Circularity Index using Image J, where an index of 1 signifies
a perfect circle, and the values approaching 0.00 signify elongated shapes. As shown in
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Figure 5.9: (A) Distribution of IQGAP1 signals in MDA-MB-231 cells expressing α6-tubulin
mutants. Cells stably expressed the S165D- or S165N α-tubulin mutant, or the empty vector (VC,
control). Images were acquired by 63X oil immersion lens. Results are representative of three
independent experiments. Note the strong IQGAP signals near membrane ruffles in control cells
(VC, empty vector) and in cells expressing the S165D mutant. (B) Images of cells stained with
nuclei and Cell-mask membrane stain (Life Technologies) exhibit morphologies taken with a 40X
objective. (C) Membrane-stained images for each condition were quantified for circularity index
shown graphically (index value towards 1.00 signifies perfect circle). Student’s t-test was used to
+
measure the statistical significance between the mutants and their corresponding control ( p<0.01,
* p<0.001) with n= 9-11, where n = number of cells per conditions.
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Figure 5.10: Western blot confirming stable expression of S165D and S165N myc-tagged-αtubulin mutants in MDA-MB-231 cells. Using whole cell lysates (40 µg per sample), western blot
analysis was performed. The blot was probed with polyclonal rabbit myc antibody (1:1000, Cell
Signaling Technology) to detect the signals of myc-tagged tubulin, and DM1A-α-tubulin mousemonoclonal antibody (1:20,000) to confirm the presence of α-tubulin. β-actin (1:5000, Cell
Signaling Technology) was used as a loading control. Results are a representative of two
independent experiments.

Figure 5.9C, the vector control or S165N cells displayed a higher degree of circular
morphology (stubby-like appearances) while the S165D had a lower circularity index value.
This observation suggests that S165D-expressing stable MDA-MB-231 cells gained
directionality in migration that is characterized by elongated shapes (as distinct in staining).
Although the pseudo-phosphorylated state confers morphological distinctions and enhanced
cell motility, there was no correlation with the distribution of IQGAP. That is, cells
expressing either mutant resulted in IQGAP signals that were distributed mainly in
cytoplasmic regions with some cells displaying signals near membrane ruffles. The
occurrence of IQGAP1 near cell-leading edges was more frequent with S165D than in
S165N, but was even higher in parental cells (Figure 5.9A).

5.4: Western blot and protein expression
MDA-MB-231 cells stably expressing myc-tagged-S165D or S165N-α-tubulin were
confirmed by preparing whole cell lysis and characterizing in an 8% polyacrylamide gel. The
results confirmed stable expression of myc-tagged S165D or S165N-α-tubulin in these cells
as shown in Figure 5.10. Under both conditions, strong signals were seen near 55 kDa with
myc-antibody which was not present in the control (empty vector) cells. This corresponded to
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Figure 5.11: Restriction digestion of one of each of the subclones of α-tubulin in the EGFP_N1
vector. Band near 6kb is of empty vector (EGFP-N1) and α-tubulin gene near 1.5 kb obtained after
restriction digestion with BamHI and NotI (Methods). The samples were loaded into a 1% agarose
gel in the following order: marker (lane 1), S165D clone 4 (lane 2), and S165N clone 5 (4).

the α-tubulin position. Interestingly, the band of myc-tagged-S165D-α-tubulin was higher
compared to the phospho-resistant S165N form; the higher apparent mass, as previously
observed with pure, recombinant α6-tubulin phosphorylated by pure, recombinant PKCα
(Abeyweera et al., 2009).

5.5: Generating stable cells with mutants of α-tubulin
For studying the effects of mutants in a mouse model, stable cell lines are required which can
constitutively express the mutants tagged with a fluorescent protein that will enable to track
them in vivo (mice model). For this purpose, the mutants – S165D and S165N-α-tubulin were
subcloned from pcDNA vector to an EGFP-N1 plasmid (Methods). Figure 5.11 shows the
results after restriction digestion of one of each of the subclones in plasmid EGFP-N1
containing a mutant tubulin gene (Methods).
At least three subclones that have the insert (~1.5kb, tubulin gene) in the corresponding
EGFP-N1 vector were selected for further confirmation by protein expression in cells. MDAMB-231/luc cells which stably express firefly luciferase gene along with Neomycin
resistance gene, is suitable for generating stable cell lines with mutants. One of each of the
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plasmids were used to transfect the MDA-MB-231/luc cells with Lipofectamine (Methods),
followed by selection at different strengths of Neomycin, and a final maintenance at
300ug/ml. Whole cell lysates were prepared from each of the stable mutant expressing MDAMB-231/luc cells, followed by confirming the protein expression by myc-antibody and
DM1A-α-tubulin. These cells had a low potential of expressing transfected proteins, hence,
the bands were not distinctly detected in a western blot (data not shown). There are several
reports accounting for the difficulties in generating stable cells with EGFP-tagged proteins or
the gradual loss of the EGFP-signal in stable cells. To overcome this problem, MDA-MB-231
cells already stably expressing the mutants – S165D or S165N-α-tubulin (bearing a neomycin
selection marker) were transfected with a luciferase gene expressing pGLA4.1 vector
(hygromycin gene). Transfected cells were selected with dual selection drugs – neomycin
(300 µg/ml) for maintaining the stable expression of mutants of α-tubulin and different doses
of hygromycin (15000 µg/ml - 400 µg/ml) to select the cells, which express both the proteins.
Finally, the cells that survived both selection pressures (300 µg/ml G418, and 400 µg/ml
hygromycin) were confirmed by luminescence assay for luciferase protein expression (Bright
GloTM luciferase assay, Promega). Briefly, the cells prior to the assay, were treated with a
volume of Bright GloTM reagent (prepared according to the manufacturer’s protocol) equal to
the culturing medium of cells (for 96 well plate, 100µl of reagent added to 100µl of medium,
per well). They were incubated for 5-8 mins before measuring the luminescence by a 96-well
plate reader equipped with a luminometer. Addition of the reagent to complete medium or
parental MDA-MB-231 cells corresponded to the blank and negative control, respectively.
The results confirmed successful stable expression of luciferase protein in S165D and
S165N-myc-tagged α6-tubulin expressing MDA-MB-231 cells (see Figure 5.12).
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Figure 5.12: Luminescence assay with MDA-MB-231 cells stably expressing S165D or S165N-αtubulin and luciferase. Cells stably expressing either of the two tubulin mutants were transfected
with luciferase (Methods), and maintained with hygromycin (400 µg/ml) along with G418 (300
µg/ml). The selected clones were plated in a 96-well plate to perform the luciferase assay which
consisted of 100 µl luciferase Bright Glo reagent (Promega) added to 100 µl complete medium per
well, followed by incubation for 6-8 min before measuring luminescence. The parental MDA-MB231 cells (untransfected) were used as a negative control. The luminescence for each construct
was plotted graphically as a percentage of the parental cells. The results showed successful stable
expression of luciferase protein in S165D and S165N-α-tubulin mutant expressing cells.

5.6: Discussion
In this section, we have primarily focused on characterizing the α6-tubulin mutants (S165D
and S165N) by tools that delineate their behavior in vivo. In previous chapters, we have
reported extensive work with the tubulin mutants in monolayer-cell cultures. Based on our
live and fixed cell imaging, dynamicity studies, and partitioning experiments, we concluded
that the phospho-α-tubulin contribute a dynamic property to the MTs, which, along with an
increased activation of Rac1 near cell membranes, facilitate migration. Increased migration
and invasiveness are two hallmarks of metastatic breast cancer cells. The 3D-cell culture
reported herein allowed us to study both the normal and malignant phenotypes of breast cells.
In a 3D-environment, cells behave similar in vivo; hence this provides an ideal platform for
studying the genes that regulate the glandular epithelial structures in normal state and also in
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Figure 5.13: Categorization of breast cell colonies from MDA-MB-231 cells stably expressing a
α6-tubulin mutant. One MCF-10A acini treated with DAG-lactone (as mentioned earlier) is shown
under round-category of breast acini morphology. A schematic diagram (adapted from (Kenny et
al., 2007)) is shown depicting the morphological features of each category. Images representative
of each morphological feature taken under different conditions by 10x objective at bright field are
included.

tumor formation. The study of α6-tubulin mutants in a 3D-environment was therefore
essential in determining their mechanistic roles in the morphogenesis of glandular epithelium.
The MCF-10A cells when grown in 3D-Matrigel, exhibited characteristic features of a
normal glandular epithelial structure. DAG-lactone treatment of these structures perturbed
their well-defined basement membranes to an extent. However, the results were not
conclusive. To dissect the exact roles of phospho-α-tubulin in glandular morphogenesis, we
extended our 3D-studies to MDA-MB-231 cells stably expressing either mutant – S165D or
S165N. The results were highly revealing. The S165D-α6-tubulin expressing cells exhibited
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remarkably large grape-like structures having intense cell-cell adhesion and compact
aggregation. They formed multi-acinar structures which is associated with the filling up of
the hollow luminal space. This can occur when oncogenes that enhance proliferation are coexpressed along with those which inhibit apoptosis, or when the oncogene ErbB2 is
expressed (which induces both) (Debnath et al., 2002), (Debnath et al., 2003). Two human
breast cell lines belonging to this grape-like multiacinar morphology are SK-BR-3 and MDAMB-361, both of which have a profound expression of the ErbB2 gene (Kenny et al., 2007).
On the other hand, we observed that the S165N-mutants formed smaller mass or grape-like
structures, and they seldom had small protrusions connecting adjacent structures. The
aggregates formed by this mutant lacked tight cell-cell adhesions. The control MDA-MB-231
cells displayed star-like morphologies having invasive phenotypes. Other known cell lines
belonging to this group are MDA-MB-436 and BT-549 cells.
A comparative study of different protein expression profiles by Western blot across different
morphologies in 3D has shown a direct correlation of a multiacinar structure with an elevated
expression of the ErbB2 gene. The mass-like or the rounded shaped acini formed by noninvasive cells usually displayed stronger E-cadherin and β-catenin signals, which were not
seen with highly metastatic cells forming either stellate structures or cells like SK-BR-3 of
known tumorigenicity forming grape-like structures (Kenny et al., 2007). A schematic
diagram of our results along with basic classification of 3D-acini (adapted partially from
Kenny et al., 2007) is shown in Figure 5.13. We hypothesize that cells upon expressing
phosphorylated-α6-tubulin attain a complex multiacinar structure by filling up of the luminal
space by acting in concert with other anti-apoptotic and/or proliferative genes. Nuclear
Hoechst staining strengthened our conclusion that under the two conditions of increased cell
migration, either with S165D or parental 231 cells, there are more nuclei per structure as
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compared to the S165N mutant. The total number of nuclei per assembly correlated with the
type and size of the acinar structure.
With cells grown in monolayer culture, assay of proliferation of cells expressing an α6tubulin mutant did not show any striking results would indicate a minimal This finding
suggests that under 2D growth assay conditions, the functioning of some proteins may have
been altered or affected such that their most obvious roles were only discerned when grown
in a 3D-Matrigel mimicking in vivo conditions. Expression of phospho-α-tubulin in MDAMB-231 cells and their maintenance in a microenvironment might have affected cell
signaling pathways, which resulted either in an up-regulation of anti-apoptotic genes, or
facilitated interaction of proteins with phospho-α-tubulin. The resulting morphologies of the
acini attained under different conditions are therefore the obvious outcome of those genes
that either act alone, or in concert with MTs bearing phospho-α-tubulin.
The 3D-model system has indeed provided us with a wealth of information on the behavioral
properties of cells when grown in a microenvironment mimicking the in vivo system. It has
provided us with a platform for examining the roles played by different genes when upregulated in malignant conditions compared to the normal state. However, based on our
insufficient understanding of cancer biology and unsolved complexities associated with it, it
is experimentally difficult to address more than two or three factors involved in
morphogenesis of glandular epithelium, acting either singly or in a concerted way.

5.7: Future work
Study of the mutants of α6-tubulin in a mouse model will be the most obvious extension to
the research done with live or fixed cells and in a 3D-environment mimicking the in vivo
conditions. For tracking the gradual development and morphogenesis of tumors in a mouse,
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we need to tag the 231 cells with a detectable reporter that will reliably help to track the
location of cells in vivo.For this purpose, the S165D and S165N-expressing stable 231-cells
were prepared such that they have a stable expression of a luciferase gene. Both of the stable
cell lines are transfected with the luciferase gene, selected and maintained by hygromycin
selection pressure in addition to a G418 dose required for the maintenance of α6-tubulin
mutant-stable cells. On surviving the dual selection pressure, the cells will therefore stably
express the α6-tubulin mutants and luciferase genes. The stable expression of the protein(s)
will be confirmed by Western blot and luminescence assay by using a luminometer. The
clones once established can then be cultured in a tissue culture dish first to determine the
dose and the duration required for the maintenance of the stable proteins. This will be
followed by implantation of the cells containing either mutant into the animal. The gradual
formation of tumors, morphologies, and other associated changes due to each tubulin mutant
can be monitored using the luciferase reporter gene in vivo by bioluminescence imaging
(IVIS) followed by data analysis (quantitation) (Bhaumik and Gambhir, 2002). This can be
followed by isolation of tumors, studying protein profiles by Western blot, RT/PCR, and
immunohistochemistry (Frick et al., 2013).
The investigation of the influence of phosphorylated α6-tubulin on the correlation of 231 cell
migration and protein interactions in vivo is a novel contribution and therefore provides an
avenue for further investigation of their contribution to mammary gland development.
Continuing this work in an animal model will therefore help to establish the complete role of
phospho-α-tubulin in tumor formation and breast cancer progression. This research will help
to establish phospho-α-tubulin as a biomarker for breast cancer progression, which could
make it a potential therapeutic target.
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Chapter 6: Concluding Statement

Cytoskeletal elements are comprised of actin filaments (F-actin), microtubules (MT) and the
intermediate filaments, all of which play intricate roles in sustaining fundamental processes
like cell division, migration, intracellular transport, and signaling pathways. Furthermore, the
cytoskeletal proteins are associated with human pathological conditions, some of which
include cardiovascular diseases, neurodegenerative diseases, and cancer. The actin
cytoskeleton and MTs constitute the highly dynamic and versatile polymers that are capable
of organizing cell organelles, determining cell shape and polarity during cell morphogenesis,
and generating the forces (pushing and contractile) required for cell migration. Cancer is a
heterogeneous disease that encompasses uncontrolled cell division, proliferation, enhanced
migration (invasion and metastasis), and disruption of polar morphology of cells. Since the
actin cytoskeleton and MTs are key players in maintaining these biological events in normal
cells, they are therefore attractive targets for drugs to be used for chemotherapeutic purposes
in cancer treatment.
Several

post-translational

modifications

(PTMs)

like

acetylation,

tyrosination,

polyglutamylation, or microtubule-targeting agents (MTAs), are known to alter the normal
functioning machineries of MTs by changing their mass or perturbing their dynamicity
(Azarenko et al., 2008), (Kamath et al., 2006). Previous findings have shown that there is a
high evidence of certain PTMs of MTs in breast tumors. To date, most of these studies have
associated β-tubulin with tumor aggressiveness, and several MTAs have been designed
against them (Akhmanova and Steinmetz, 2008; Honore et al., 2005; Garnham and Roll-‐
Mecak, 2012). The other two variants of tubulin namely – α and γ – have remained
comparatively under-explored. In particular, while there are a few reports relating post113
	
  

	
  
	
  

translational modifications of α-tubulin with breast cancer (Honore et al., 2005; Jordan and
Wilson, 2004; Peris et al., 2006; Hammond et al., 2008), there is no record linking its
phosphorylation to the disease.
Protein kinase C (PKC) isoenzymes exhibit different expression profiles depending on the
particular cancer type. A few isoforms of PKC – particularly α, β, and δ are expressed in
abundance in various tissues, and have been studied extensively. The majority of studies with
PKC isoforms have shown that PKCα (a conventional isoform), and PKCδ (a novel isoform)
-- both sensitive to DAG-lactone – can be highly expressed in breast cancers, and have been
correlated with the progression of metastatic breast cells (Urtreger et al., 2012; Lonne et al.,
2010). It is noted that some metastatic human breast tumors show down-regulation of PKCα.
In such cases, it is predicted that PKCδ overexpression would produce similar phenotypic
outcomes since both α and δ are known to produce cell motility and to generate similar
protein phosphorylation profiles (Chen et al., 2012). Nevertheless, both in vivo and in vitro
studies have shown that PKCα is associated with enhanced motility, proliferation and
invasion of cancer cells, along with reduced apoptosis (Koivunen et al., 2006). Based on such
growing evidence, PKCα has emerged as a potential biomarker for breast cancer progression
(Lonne et al., 2010; Konopatskaya and Poole, 2009). It is therefore necessary to identify the
substrates of PKCα and investigate their roles in metastasis of breast cells.
Previous work from our laboratory had identified one such substrate of PKCα, α6-tubulin, an
isoform of α-tubulin, in non-motile human breast epithelial MCF-10A cells that express very
low levels of PKC (including the conventional PKCα isoform) (Abeyweera et al., 2009). An
overexpression of PKCα resulted in a migratory behavior in these non-motile cells. Since α-β
dimers constitute the core unit of MT filaments, it was hypothesized that phosphorylation of
one of the subunits by PKCα might contribute to enhanced migration of these cells. By using
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pseudo-phosphorylated

and

phosphorylation-resistant

mutants,

it

was

found

that

phosphorylation of α6-tubulin by PKCα reproduces the acquired motility phenotype that had
been observed upon overexpressing PKCα (Abeyweera et al.. 2009). However, the
underlying mechanism that drives cell motility under this condition remained unknown. The
current work is novel since it identifies the mechanism behind the enhanced migration
observed in MCF-10A cells upon phosphorylation of α-tubulin by PKCα. Furthermore, this
work explores the possible interaction of MTs bearing phospho-α-tubulin with other
membrane-bound proteins like small GTPases (Rac1, Cdc42 or RhoA), IQGAP, and
MARCKS, which are all known to participate in cell migration. Our findings are
schematically depicted in the model in Figure 6.1.
Quantitative analysis of live-cell imaging results showed that upon phosphorylation by DAGlactone in MCF-10A cells, MTs acquire an enhanced dynamicity accompanied by increased
rates and durations of growth compared to other phases of their life-cycle. Similar results
were observed with the expression of pseudo-phosphorylated (S165D) mutants in these cells.
The phospho-resistant (S165N) mutant showed significantly suppressed dynamic events
similar to parental MCF-10A cells. To dissect the role of site-specific phosphorylation in
enhancing such dynamic behavior, highly metastatic MDA-MB-231 cells, which already
express high levels of PKCα, were transfected with each mutant. In this case, the S165Nmutant suppressed the dynamicity of MTs by a significant reduction in growth duration and
rate as compared to the intrinsically high dynamic parameters of MTs in parental or S165Dexpressing 231 cells. Thus, phosphorylation contributes an enhanced dynamicity in MTs by
increasing growth phase duration and rate, along with shorter and more infrequent pause
intervals. Site-specific phosphorylation therefore stabilizes the MTs, resulting in fewer
catastrophes, longer growth and formation of ‘U’-like structures near the cell leading edges.
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Figure 6.1: Model illustrating the role of PKCα in the migration of MCF-10A breast epithelial
cells. Each microtubule is composed of 13 protofilaments. Here, only one such protofilament
representing each MT has been shown. In the non-motile condition (left), cells exhibit less
dynamic, shorter, unstable MTs, and localization of E-cadherin near the cell membrane. Upon
activation of PKCα (either DAG-lactone mediated or PKCα overexpression), these cells acquire
motility characterized by extended lamellipodia and enhanced migration rate. PKCα
phosphorylates its substrate α6-tubulin, which is incorporated to a great extent in MT polymers
(filaments), thereby increasing dynamicity, conferring an overall stability, and forming elongated
structures of MTs which extend to the base of lamellipodia that are rich in actin filaments. The
elongated MTs result in the activation of Rac1 near membranes in an unknown mechanism.
Another substrate of PKCα, IQGAP1, upon phosphorylation gets transported to the membrane
periphery (mechanism unknown), where it interacts with active Rac1, and actin-filaments,
generate a driving force and facilitates enhanced cell migration. Note IQGAP1 and E-cadherin
display complementary localization in a migrating cell. Taken together, this model describes a
possible mechanistic pathway of enhanced migration in breast cancer cells that express high levels
of PKCα.
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Attainment of relative stability due to phosphorylation was confirmed by quantitation of the
myc-tagged α-tubulin (wild-type in presence of DAG-lactone, and mutants) retained in MTs
in the presence of low doses of the MT-depolymerizing drug nocodazole. Under the
conditions of phosphorylation, either due to DAG-lactone treatment or upon expressing
S165D-mutant, there was a higher retention of phospho-α-tubulin in MT protofilament,
chiefly near the periphery of lamellipodia. Experiments with MT-fractionation assay showed
an increased partitioning of phospho-α-tubulin (due to DAG-lactone treatment or S165Dmutant) in the polymer fraction (insoluble) of MTs vs. the monomer/dimer (soluble) pool. An
increased partitioning was also associated with a higher degree of incorporation of phosphoα-tubulin in existing MTs as measured quantitatively by a co-localization index in wild-type
cells treated with DAG-lactone or cells expressing S165D-mutant compared to their
respective controls (DMSO or S165N-mutant). The above changes due to phosphorylation
are depicted in the model shown in Figure 6.1.
The small GTPases like Rac1 are known to be activated locally near membrane protrusions
by MTs, which along with actin-filaments enable cell migration (Waterman-Storer et al.,
1999). Our results from a pull-down assay showed that stable and elongated MTs, due to sitespecific phosphorylation of α-tubulin, resulted in an increased expression of active Rac1.
Currently, the specific pathway by which Rac1 is activated by elongating MTs is not known.
The other small GTPases, like Cdc42 or RhoA, showed no differences in their activation
status with the mutants of α-tubulin. This concurs with previous findings from our laboratory
– namely, only the dominant negative (dn) form of Rac1 (but not the dn forms of either
Cdc42 or RhoA) impedes the acquired motility in PKCα overexpressing cells (Sun and
Rotenberg, 1999).
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Besides studying in detail the mechanistic pathway of enhanced cell migration mediated by
MTs expressing phospho-α-tubulin, we also explored the role of these phosphorylated MTs in
the transport of a cargo protein, MARCKS. Upon phosphorylation by PKC, MARCKS is
released from membrane to the cytoplasm and this event corresponds to enhanced cell
motility (Chen and Rotenberg, 2010). A journey back to the membrane is required for
maintaining cell homeostasis. MTs bearing the S165N-mutant displayed a much delayed
transport and hence, a lag in its return to the membrane.
Another substrate of PKCα is IQGAP1 (White et al., 2012; McNulty et al., 2011), which is
known to capture MTs near cell-leading edges along with Rac1, thereby increasing the pool
of MT-plus ends and facilitating in cell movement (Fukata et al., 2002). Breast tumorigenesis
is also associated with an increased expression level of IQGAP1 and its localization near
leading edges of migrating cells (Jadeski et al., 2008; Johnson et al., 2009). Our studies with
MCF-10A cells treated with a Rac inhibitor (which prevents formation of the GTP-bound
active Rac1) suggested that IQGAP1 depends on the active conformation of Rac1 to remain
bound to cell membranes. We also found that the transport of IQGAP1 from the cytoplasmic
pool to the membrane during cell movement is not dependent on MTs, since, upon expressing
the S165D-mutants of α-tubulin, there was no increase in the IQGAP1 signal near the
membrane periphery in cells treated with the Rac1 inhibitor. This opens the possibility of
some other PKC substrates that interact with IQGAP1, or phosphorylation of IQGAP itself,
that facilitates its transport within the cell. Interestingly, the E-cadherin protein and IQGAP1
showed complementary profiles in cells when treated with DAG-lactone. A complex of βcatenins and actins share a higher binding affinity to IQGAP1 than with E-cadherin; an
increase in the pool of IQGAP1 therefore facilitates the displacement of E-cadherin from the
complex resulting in the formation of a tripartite complex near cell edges. This complex helps
to tether Rac1 and to generate the driving force for cell migration.
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The above results pertain to monolayer cultures; their relevance to the three-dimensional
(3D) conditions existing in vivo was investigated by growing them in 3D using Matrigel to
simulate the basement membrane in an in vivo microenvironment. In the presence of MTs
bearing phospho-α-tubulin – both in MCF-10A cells treated with DAG-lactone and in MDAMB-231 cells stably expressing the S165D-mutant – the 3D clusters acquired a phenotype
that has been associated with tumorigenicity (Kenny et al., 2007; Debnath et al., 2002). One
aspect of tumorigenicity is enhanced invasion (metastasis) by cells with a mesenchymal
morphology. As a result of the epithelial-mesenchymal transition, cells acquire an elongated
morphology. In this regard, the degree of cell circularity was quantified in a (2D) staining
experiment performed on MDA-MB-231 cells expressing either the S165D or S165N mutant,
or the empty vector. The results were consistent with all our previous conclusions – namely
that phospho-α-tubulin was found to bestow an elongated morphology to the MDA-MB-231
cell.
Taken together, our results describe a pathway by which PKCα, through its formation of
phospho-α-tubulin, drives migration of human breast cancer cells that already express a high
level of this kinase. These findings will help to establish phospho-α-tubulin as a biomarker
for breast cancer progression with a possible application in chemotherapy.	
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